WO2010094956A1 - Triazolopyridine derivatives as p38 map kinase inhibitors - Google Patents

Triazolopyridine derivatives as p38 map kinase inhibitors Download PDF

Info

Publication number
WO2010094956A1
WO2010094956A1 PCT/GB2010/050257 GB2010050257W WO2010094956A1 WO 2010094956 A1 WO2010094956 A1 WO 2010094956A1 GB 2010050257 W GB2010050257 W GB 2010050257W WO 2010094956 A1 WO2010094956 A1 WO 2010094956A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
radical
compound
compounds
general formula
Prior art date
Application number
PCT/GB2010/050257
Other languages
French (fr)
Inventor
Harry Finch
John Montana
Monique Bodil Van Niel
Chi-Kit Woo
Jamie Knight
Bohdan Waszkowycz
Original Assignee
Pulmagen Therapeutics (Inflammation) Limited.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42232647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010094956(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0902651A external-priority patent/GB0902651D0/en
Priority claimed from GB0908069A external-priority patent/GB0908069D0/en
Priority to CN2010800078222A priority Critical patent/CN102395586A/en
Priority to SG2011058823A priority patent/SG174134A1/en
Priority to BRPI1005327A priority patent/BRPI1005327A2/en
Priority to EP10704973A priority patent/EP2398798A1/en
Priority to CA2752693A priority patent/CA2752693A1/en
Application filed by Pulmagen Therapeutics (Inflammation) Limited. filed Critical Pulmagen Therapeutics (Inflammation) Limited.
Priority to JP2011549680A priority patent/JP2012517992A/en
Priority to US13/201,716 priority patent/US8557797B2/en
Priority to MX2011008496A priority patent/MX2011008496A/en
Priority to AU2010215261A priority patent/AU2010215261A1/en
Priority to MA34175A priority patent/MA33128B1/en
Priority to EA201190119A priority patent/EA201190119A1/en
Publication of WO2010094956A1 publication Critical patent/WO2010094956A1/en
Priority to TN2011000380A priority patent/TN2011000380A1/en
Priority to IL214658A priority patent/IL214658A0/en
Priority to ZA2011/05993A priority patent/ZA201105993B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract. Background to the invention
  • Mitogen activated protein kinases constitute a family of proline- directed serine/threonine kinases that activate their substrates by dual phosphorylation. There are four known human isoforms of p38 MAP kinase, p38 ⁇ , p38 ⁇ , p38 ⁇ and p38 ⁇ .
  • the p38 kinases which are also known as cytokine suppressive anti-inflammatory drug binding proteins (CSBP), stress activated protein kinases (SAPK) and RK, are responsible for phosphorylating (Stein et al., Ann. Rep.
  • IL-1 and TNF ⁇ are biological substances produced by a variety of cells, such as monocytes or macrophages.
  • IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation (e.g. Dinarello et ai, Rev. Infect. Disease, 1984, 6, 51).
  • Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases, and it is believed that TNF can cause or contribute to the effects of inflammation in general.
  • IL-8 is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes.
  • IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes and basophils. Increase in IL-8 production is also responsible for chemotaxis of neutrophils into the inflammatory site in vivo.
  • Inhibition of signal transduction via p38 which in addition to IL-1 , TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (e.g., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for p38 kinase inhibitors (Badger et al., J. Pharm. Exp. Thera., 1996, 279, 1453-1461 ; Griswold et al, Pharmacol. Comm.,1996, 7, 323-229).
  • p38 kinase inhibitors have been described as potential agents for treating rheumatoid arthritis.
  • Stress stimuli including tobacco smoke, infections or oxidative products
  • Inhibitors of p38 have been shown to inhibit LPS and ovalbumin induced airway TNF-q IL-1 ⁇ , IL-6, IL-4, IL-5 and IL-13 (Haddad et al, Br. J. Pharmacol., 2001 , 132 (8), 1715-1724; Underwood et al, Am. J.
  • p38MAPK pathway in various diseases has been reviewed by P. Chopra et al. (Expert Opinion on Investigational Drugs, 2008, 17(10), 1411-1425). It is believed that the compounds of the present invention can be used to treat p38 mediated diseases such as: asthma, chronic or acute bronchoconstriction, bronchitis, acute lung injury and bronchiectasis, pulmonary artery hypertension, tuberculosis, lung cancer, inflammation generally (e.g.
  • inflammatory bowel disease arthritis
  • neuroinflammation pain, fever, fibrotic diseases, pulmonary disorders and diseases (e.g., hyperoxic alveolar injury)
  • cardiovascular diseases post-ischemic reperfusion injury and congestive heart failure
  • cardiomyopathy stroke
  • ischemia reperfusion injury
  • renal reperfusion injury brain edema
  • neurotrauma neurotrauma and brain trauma
  • neurodegenerative disorders central nervous system disorders
  • liver disease and nephritis gastrointestinal conditions, ulcerative diseases, Crohn's disease
  • ophthalmic diseases ophthalmological conditions, glaucoma, acute injury to the eye tissue and ocular traumas
  • diabetes diabetic nephropathy, skin-related conditions, myalgias due to infection, influenza, endotoxic shock, toxic shock syndrome, autoimmune disease, graft rejection, bone resorption diseases, multiple sclerosis, psoriasis, eczema, disorders of the female reproductive system, pathological (but non-malignant) conditions
  • TNF chronic release of active TNF can cause cachexia and anorexia, and TNF can be lethal.
  • TNF has also been implicated in infectious diseases. These include, for example, malaria, mycobacterial infection and meningitis.
  • viral infections such as HIV, influenza virus, and herpes virus, including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella- zoster virus (VZV), Epstein-Barr virus, human herpes virus-6 (HHV-6), human herpesvirus-7 (HHV7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.
  • HSV-1 herpes simplex virus type-1
  • HSV-2 herpes simplex virus type-2
  • CMV cytomegalovirus
  • VZV varicella- zoster virus
  • Epstein-Barr virus Epstein-Barr virus
  • human herpes virus-6 HHV-6
  • P38 kinase inhibitors have been reviewed by G. J. Hanson (Expert Opinions on Therapeutic Patents, 1997, 7, 729-733) J Hynes et al. (Current Topics in Medicinal Chemistry, 2005, 5, 967-985), C. Dominguez et al (Expert Opinions on Therapeutics Patents, 2005, 15, 801-816) and L. H. Pettus & R. P. Wurtz (Current Topics in Medicinal Chemistry, 2008, 8, 1452-1467).
  • P38 kinase inhibitors containing a triazolopyridine motif are known in the art, for example WO07/091152, WO04/072072, WO06/018727. Summary of the Invention
  • the compounds of the present invention are inhibitors of p38 mitogen activated protein kinase ("p38 MAPK”, “p38 kinase” or “p38”), including p38 ⁇ kinase, and are inhibitors of cytokine and chemokine production including TNF ⁇ and IL-8 production. They have a number of therapeutic applications, in the treatment of inflammatory diseases, particularly allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases such as chronic obstructive pulmonary disease ("COPD”) and asthma. They are therefore particularly suited for pulmonary delivery, by inhalation by nose or mouth.
  • inflammatory diseases particularly allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases such as chronic obstructive pulmonary disease ("COPD”) and asthma.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • R 1 is C r C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl which is optionally substituted, 5- or 6-membered monocyclic heteroaryl which is optionally substituted or a radical of formula (II)
  • Y is -O- or -S(0) p - wherein p is O, 1 or 2;
  • W is a bond, -NH- or -C(R A )(R B )-, wherein R A and R B are independently H, methyl, ethyl, amino, hydroxyl or halo; and R 2 is a radical of formula (IIIA), (IMB) or (NIC):
  • R 5 is H or F
  • R 7 is -CH 3 , -C 2 H 5 , -CH 2 OH, -CH 2 SCH 3 , -SCH 3 or -SC 2 H 5 ;
  • R 8 is -CH 3 or -C 2 H 5 ; and each occurrence of R 6 is independently H, C1-C 6 alkyl, hydroxy or halo; or a single occurrence of R 6 is a radical of formula (IVA), (IVB) or (IVC)
  • R 61a and R 61b are H, alkyl, or R 61a and R 61b may be joined together with the nitrogen to which they are attached to form a heterocyclic ring optionally containing a further heteroatom selected from N and O.
  • the invention includes pharmaceutical compositions comprising a compound of the invention, together with one or more pharmaceutically acceptable carriers and/or excipients. Particularly preferred are compositions adapted for inhalation for pulmonary administration.
  • the invention includes the use of a compound of the invention for the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity. The treatment of obstructive or inflammatory airways diseases is a preferred use.
  • obstructive or inflammatory airways diseases are potentially treatable with the compounds of the present invention, in particular an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic eosinophilic pneumonia, asthma, COPD, COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension, chronic inflammatory diseases including cystic fibrosis, broncietasis and pulmonary fibrosis (Idiopathic).
  • an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic eosinophilic pneumonia, asthma, COPD, COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated
  • Efficacy is anticipated when p38 kinase inhibitors are administered either locally to the lung (for example by inhalation and intranasal delivery) or via systemic routes (for example, oral, intravenous and subcutaneous delivery).
  • p38 kinase inhibitors are administered either locally to the lung (for example by inhalation and intranasal delivery) or via systemic routes (for example, oral, intravenous and subcutaneous delivery).
  • (C a -C b )alkyr wherein a and b are integers, refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
  • a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n- hexyl.
  • Carbocyclic refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl.
  • divalent cycloalkylene radical refers to a cycloalkyl radical having two unsatisfied valencies such as 1 ,3-cyclopentylene and 1 ,4- cyclohexylene, as follows:
  • divalent arylene radical refers to a monocyclic or bicyclic aryl radical having two unsatisfied valencies such as 1 ,3-phenylene or 1 ,4-phenylene as follows:
  • heteroaryl refers to a mono- or bicyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, which are directly linked by a covalent bond.
  • Illustrative examples of such radicals are thienyl, benzothienyl, furyl, benzofuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benzotriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
  • divalent heteroarylene radical refers to a monocyclic or bicyclic heteroaryl radical having two unsatisfied valencies such as the following:
  • substituted as applied to any aryl or heteroaryl moiety herein means substituted with at least one substituent, for example selected from (CrC 6 )alkyl, (CrCe) fluoroalkyl, (CrC ⁇ Jalkoxy (including methylenedioxy and ethylenedioxy substitution on adjacent carbon atoms of an aromatic ring), (Ci-C 6 )fluoroalkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, benzyloxy-(CrC 6 )alkyl, (CrC 6 )alkoxy-(Ci-C 6 )alkoxy, benzyloxy-(Ci-C 6 )alkoxy, hydroxy, hydroxy(Ci-C 6 )alkyl, hydroxy(Ci-C 6 )alkoxy, mercapto, mercapto(Ci-C 6 )
  • Compounds of the invention may exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and frans-forms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers may be prepared by the application of adaptation of known methods (e.g. asymmetric synthesis).
  • salt includes base addition, acid addition and ammonium salts.
  • compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. ⁇ /-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, ⁇ /-ethyl piperidine, dibenzylamine and the like.
  • bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. ⁇ /-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, ⁇ /-
  • Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like.
  • hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
  • organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic,
  • Those compounds (I) which have a basic nitrogen can also form quaternary ammonium salts with a pharmaceutically acceptable counter-ion such as ammonium, chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • a pharmaceutically acceptable counter-ion such as ammonium, chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like.
  • Individual compounds of the invention may exist in several polymorphic forms and may be obtained in different crystal habits.
  • the compounds may also be administered in the form of prodrugs thereof.
  • prodrugs certain derivatives of the compounds which may be active in their own right or may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of the invention having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as 'prodrugs'.
  • Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and V.J. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association; CS. Larsen and J. ⁇ stergaard, Design and application of prodrugs, In Textbook of Drug Design and Discovery, 3 rd Edition, 2002, Taylor and Francis).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
  • the divalent radical -W-[A]-Y- may be, for example, any of the corresponding radicals in the specific Example compounds below.
  • that radical may be one of the following formulae (B) - (J):
  • compounds may have formula (IA 1 ):
  • Y is O or S
  • R 2 is as defined in claim 1
  • R 1 is phenyl, 5- or 6- membered monocyclic heteroaryl or a radical of formula (II) as defined in relation to formula (I) above.
  • R 1 may be a group of formula (II) as defined in relation to formula (I) above wherein the group -NR 3 R 4 is morpholinyl.
  • R 1 may be isopropyl or 2,6-dichlorophenyl.
  • R 2 may be a radical of formula (NIC) as defined in relation to formula (I) above, wherein R 7 and R 8 are each methyl.
  • R 2 may have formula (HID), (HIE), (IMF) or (IMG):
  • R 2 may be a radical of formula (I I IA) as defined in relation to formula (I), wherein m is 0.
  • MIB radical of formula
  • the divalent radical A may be a six-membered ring such as phenylene or pyridinylene, linked to Y and W in a 1 ,3 (meta) or 1 ,4 (para) orientation.
  • the divalent radical A may be a cyclohexylene radical linked to W and Y in a trans-1 ,4 orientation.
  • W may be -CH 2 -.
  • the compounds of the invention are p38MAPK inhibitors, and thus may have utility for the treatment of diseases or conditions which benefit from inhibition of the p38 enzyme.
  • diseases and conditions are known from the literature and several have been mentioned above.
  • the compounds are generally of use as anti-inflammatory agents, particularly for use in the treatment of respiratory disease.
  • the compounds may be used in the treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, or smoking-induced emphysema, intrinsic (non-allergic asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, steroid resistant asthma, neutrophilic asthma, bronchitic asthma, exercise induced asthma, occupational asthma and asthma induced following bacterial infection, cystic fibrosis, pulmonary fibrosis and bronchiectasis.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • ARDS acute respiratory distress syndrome
  • pulmonary emphysema or smoking-induced emphysema
  • intrinsic (non-allergic asthma and extrinsic (allergic) asthma mild asthma, moderate asthma, severe asthma, steroid resistant asthma
  • neutrophilic asthma
  • the compounds with which the invention is concerned are p38 kinase inhibitors, and are useful in the treatment of several diseases for example inflammatory diseases of the respiratory tract.
  • diseases for example inflammatory diseases of the respiratory tract.
  • diseases include asthma, rhinitis, allergic airway syndrome, bronchitis and chronic obstructive pulmonary disease.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range for oral administration will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a human, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses.
  • the daily dose range for inhaled administration will lie within the range of from about 0.1 ⁇ g to about 1mg per kg body weight of a human, preferably 0.1 ⁇ g to 50 ⁇ g per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • inhaled administration is preferred.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulfate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
  • the active ingredient may also be administered parenterally in a sterile medium.
  • the drug can either be suspended or dissolved in the vehicle.
  • adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • compounds of the invention may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers.
  • the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze- drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
  • a composition of the invention may be prepared as a suspension for delivery from a nebuliser or as an aerosol in a liquid propellant, for example for use in a pressurised metered dose inhaler (PMDI).
  • PMDI pressurised metered dose inhaler
  • Propellants suitable for use in a PMDI are known to the skilled person, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (CCI 2 F 2 ) and HFA-152 (CH 4 F 2 and isobutane)
  • a composition of the invention is in dry powder form, for delivery using a dry powder inhaler (DPI).
  • DPI dry powder inhaler
  • Microparticles for delivery by administration may be formulated with excipients that aid delivery and release.
  • microparticles may be formulated with large carrier particles that aid flow from the DPI into the lung.
  • Suitable carrier particles are known, and include lactose particles; they may have a mass median aerodynamic diameter of greater than 90 ⁇ m.
  • an example is:
  • the active compounds may be dosed as described depending on the inhaler system used.
  • the administration forms may additionally contain excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
  • Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: (1) corticosteroids, such as fluticasone propionate, fluticasone furoate, mometasone furoate, beclometasone dipropionate, ciclesonide, budesonide, GSK 685698, GSK 870086, QAE 397, QMF 149, TPI-1020; (2) ⁇ 2-adrenoreceptor agonists such as salbutamol, albuterol, terbutaline, fenoterol, and long acting ⁇ 2-adrenoreceptor agonists such as salmeterol, indacaterol, formoterol (including formoterol fumarate), arformoterol
  • saline or mannitol or surfactant
  • a peptide mucolytic for example recombinant human deoxyribonoclease I (dornase-alfa and rhDNase) or helicidin
  • antibiotics for example azithromycin, tobramycin and aztreonam
  • non-selective COX-1 / COX-2 inhibitors such as ibuprofen or ketoprofen
  • COX-2 inhibitors such as celecoxib and rofecoxib
  • VLA-4 antagonists such as those described in WO97/03094 and WO97/02289
  • TACE inhibitors and TNF- ⁇ inhibitors for example anti-TNF monoclonal antibodies, such as Remicade and CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel
  • inhibitors of matrix metalloprotease for example MMP-12
  • human neutrophil elastase inhibitors such as ONO-6818 or those described in WO2005/026124, WO2003/053930 and WO06/082412
  • A2b antagonists such as those described in WO2002/42298
  • modulators of chemokine receptor function for example antagonists of CCR3 and CCR8
  • compounds which modulate the action of other prostanoid receptors for example a thromboxane A 2 antagonist
  • DP1 antagonists such as MK-
  • a suitable coupling agent such as 2-(7-aza-1/-/-benzotriazole-1-yl)- 1 ,1 ,3,3-tetramethyluronium hexafluorophosphate, 1 -ethyl-3-(3'- dimethylaminopropyl) carbodiimide or dicyclohexylcarbodiimide in the presence of a base such as diisopropylethylamine or triethylamine.
  • the reaction may take place in a suitable solvent such as dichloromethane, ⁇ /, ⁇ /-dimethylformamide or tetrahydrofuran at a range of temperatures, preferably at room temperature.
  • compounds of formula (l-a) may be prepared from compounds of general formula (IX) by reaction with a suitable halogenating agent wich as oxalyl chloride or thionyl chloride in the absence or presence of a solvent such as dichloromethane or ⁇ /, ⁇ /-dimethylformamide at a range of temperatures, preferably from room temperature to 100 0 C, followed by reaction with an amine of general formula (X), using a suitable base such as diisopropylethylamine, in a suitable sovent such as tetrahydrofuran at a range of temperatures, preferably from room temperature to 80 0 C.
  • a suitable halogenating agent wich as oxalyl chloride or thionyl chloride in the absence or presence of a solvent such as dichloromethane or ⁇ /, ⁇ /-dimethylformamide at a range of temperatures, preferably from room temperature to 100 0 C
  • a suitable base such as diisopropyleth
  • R is H or alkyl
  • a suitable calatyst such as copper (I) iodide, copper (I) chloride, palladium acetate, tetrakis(triphenylphosphine)palladium (0) or dichloro(1 ,1'-bis(diphenylphosphino)ferrocene)palladium (II), in the absence or the presence of a suitable ligand such as (2,9-dimethyl)-1 ,10-phenanthroline, proline, 1 ,2-cyclohexyldiamine or a phosphine, using a base such as cesium carbonate, potassium hydroxide, potassium carbonate or sodium terf-butoxide.
  • a suitable calatyst such as copper (I) iodide, copper (I) chloride, palladium acetate, tetrakis(triphenylphosphine)palladium (0) or dichloro(1 ,1'
  • the reaction may take place in a suitable solvent such as toluene, N- methylpyrrolidinone or ⁇ /, ⁇ /-dimethylformamide at a range of temperatures, preferably between 40 and 150 0 C; followed, if R is alkyl, by hydrolysis according to methods known to those skilled in the art.
  • a suitable solvent such as toluene, N- methylpyrrolidinone or ⁇ /, ⁇ /-dimethylformamide at a range of temperatures, preferably between 40 and 150 0 C; followed, if R is alkyl, by hydrolysis according to methods known to those skilled in the art.
  • a suitable oxidant such as chloramine T, lead tetracetate or phenyliodine(lll) diacetate
  • a suitable solvent such as dichloromethane or ethanol
  • R 3 CHO (III) in a suitable solvent such as ethanol or tetrahydrofuran at a range of temperatures, preferably between room temperature and 8O 0 C.
  • compounds of formula (IV) may be prepared from compounds of formula (II) by reaction with a compound of general formula (Vl): R 3 CO 2 H (VI), using a suitable acylating/dehyd rating agent such as triphenylphosphine/trichloroacetonitrile in the presence of a base such as diisopropylethylamine, in a suitable solvent such as dichloromethane or acetonitrile, at a range of temperatures, preferably between room temperature and 150 0 C.
  • a suitable acylating/dehyd rating agent such as triphenylphosphine/trichloroacetonitrile
  • a base such as diisopropylethylamine
  • a suitable solvent such as dichloromethane or acetonitrile
  • compounds of formula (IV) may be prepared from compounds of formula (VII):
  • a suitable dehydrating agent such as Burgess' reagent, triphenyl phosphine and hexachloroethane, phosphorus oxychloride, acetic acid or Mitsunobu conditions
  • R b is as defined for R 2 in general formula (I), in a suitable solvent such as dimethyl sulfoxide, 1 ,4-dioxane or acetonitrile, in the presence of a base such as diisopropylethylamine at a range of temperatures, preferably between room temperature and 100 0 C.
  • a suitable solvent such as dimethyl sulfoxide, 1 ,4-dioxane or acetonitrile
  • Compounds of general formula (XIII) may be prepared from amines of general formula (X) according to known literature procedures (e.g. WO2006/009741 , EP1609789).
  • compounds of general formula (l-b) may be prepared from compounds of general formula (XII) by reaction with an amine of general formula (X), using a suitable coupling agent such as phosgene, diphosgene or triphosgene, in a suitable solvent such as dichloromethane, toluene, tetrahydrofuran or acetonitrile, using a suitable base such as triethylamine, pyridine or diisopropylethylamine, at a range of temperatures preferably between O and 100 0 C.
  • a suitable coupling agent such as phosgene, diphosgene or triphosgene
  • a suitable solvent such as dichloromethane, toluene, tetrahydrofuran or acetonitrile
  • a suitable base such as triethylamine, pyridine or diisopropylethylamine
  • a suitable reductive agent such as tin (II) chloride, iron or hydrogen gas in the presence of a catalyst such as palladium on charcoal, platinum oxide or Raney Nickel, in the presence or absence of acid such as hydrogen chloride or acetic acid, in a suitable solvent such as methanol, ethanol or ethyl acetate, at a range of temperatures, preferably between room temperature and 80 0 C.
  • R d is H, with a suitable metallated species such as butyllithium, magnesium or i-propylmagnesium chloride, in a suitable solvent such as tetrahydrofuran or diethyl ether, at a range of temperatures, preferably between - 78 0 C and room temperature.
  • a suitable metallated species such as butyllithium, magnesium or i-propylmagnesium chloride, in a suitable solvent such as tetrahydrofuran or diethyl ether, at a range of temperatures, preferably between - 78 0 C and room temperature.
  • a suitable base such as diisopropylethyiamine, potassium carbonate, sodium carbonate or sodium hydride in the absence or presence of a suitable catalyst such as potassium iodide or sodium iodide, in a suitable solvent such as dichloromethane, tetrahydrofuran or acetonitrile, at a range of temperatures, preferably between room temperature and 80 0 C.
  • Compounds of general formula (XXIII) may be prepared from amines of general formula (X), according to known literature procedures (e.g. Migliara et al. Farmaco (1992), 47(1), 111-19).
  • R c is a suitable protecting group, by deprotection according to methods known to those skilled in the art.
  • R is alkyl
  • R b NH 2 (X), wherein R b is as defined for R 2 in general formula (I) as described above.
  • R c is alkyl by deprotection according to methods known to those skilled in the art.
  • a suitable compound R d X (XXXI) by reaction with a suitable compound R d X (XXXI) using a suitable base such as lithium hexamethyldisilazide or sodium hydride in a suitable solvent such as tetrahydrofuran, DMF or diethyl ether, at a range of temperatures, preferably between room temperature and 8O 0 C.
  • a suitable base such as lithium hexamethyldisilazide or sodium hydride
  • a suitable solvent such as tetrahydrofuran, DMF or diethyl ether
  • R a is as defined for R 1 in general formula (I) by reaction with an alcohol of general formula (XXX) according to methods known to those skilled in the art.
  • HOBt 1-hydroxy-benzotriazole
  • HPLC high performance liquid chromatography
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • NMR spectra were obtained on a Varian Unity Inova 400 spectrometer with a 5mm inverse detection triple resonance probe operating at 400 MHz or on a Bruker Avance DRX 400 spectrometer with a 5 mm inverse detection triple resonance TXI probe operating at 400 MHz or on a Bruker Avance DPX 300 spectrometer with a standard 5 mm dual frequency probe operating at 300 MHz. Shifts are given in ppm relative to tetramethylsilane. NMR spectra were assigned using DataChord Spectrum Analyst Version 4.0.b21.
  • 'flash silica' refers to silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Fluka silica gel 60), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution or use of the CombiFlash ® Companion purification system or use of the Biotage SP1 purification system. All solvents and commercial reagents were used as received.
  • MS ionization method Electrospray (positive and negative ion).
  • MS ionization method Electrospray (positive and negative ion).
  • MS ionisation method Electrospray (positive ion).
  • MS ionization method Electrospray (positive and negative ion).
  • MS ionisation method Electrospray (positive ion).
  • MS ionization method Electrospray (positive and negative ion).
  • MS ionisation method Electrospray (positive/negative ion).
  • MS ionisation method Electrospray (positive/negative ion).
  • Example 1 step a To a solution of Example 1 step a (10.93 g, 24.16 mmol) in DCM (100 ml_)/EtOH (15 ml_), was added PhI(OAc) 2 (10.74 g, 33.35 mmol). The reaction was stirred at RT for 72 h, diluted with DCM (25 ml_) then washed with aq. sodium hydroxide (1 M, 25 ml.) and brine (25 ml_). The organic layer was dried (MgSO 4 ), filtered, and the filtrate was concentrated in vacuo.
  • Example 1 step b 400 mg, 0.888 mmol
  • 3-mercaptobenzoic acid 205 mg, 1.24 mmol
  • [1 ,1'- bis(diphenylphosphino)ferrocene] dichloropalladium(ll) 1 :1 complex with DCM 138 mg, 0.168 mmol
  • cesium carbonate 578 mg, 1.777 mmol
  • DMF 3 ml_
  • the reaction was degassed (x3) under argon.
  • the reaction was heated at 9O 0 C for 24 h then allowed to cool to RT, filtered, and the filtrate concentrated in vacuo to afford the title compound (422 mg, quantitative).
  • Example 1 step c (213 mg, 0.447 mmol), cyclopropanemethylamine (32 mg, 0.447 mmol), HATU (212 mg, 0.558 mmol), and DMF (3 ml_).
  • DIPEA 225 ⁇ l_, 1.34 mmol was added, the reaction was stirred at RT for 24 h then concentrated in vacuo and the crude residue purified directly by reverse phase preparative HPLC (Method 3) to afford the title compound (92 mg, 39%) as an off-white solid.
  • LCMS (Method 4): Rt 6.55 min, m/z 530 [MH + ].
  • Example 10 step a 250 mg, 1.21 mmol
  • ⁇ /-(2- bromoethyl)morpholine hydrochloride (306 mg, 1.32 mmol)
  • K 2 CO 3 500 mg, 3.62 mmol
  • DMF 20 ml_
  • the reaction was then allowed to cool to RT and concentrated in vacuo.
  • the residue was purified by FCC (DCM:MeOH, 1 :0 to 9:1) to afford the title compound (479 mg, 98%) as a yellow oil.
  • Example 10 step c A mixture of Example 10 step c (315 mg, 0.703 mmol), 5-(2,2,2- trichloroethoxycarbonyl)amino-3-ferf-butyl-1-p-tolyl-1/-/-pyrazole (299 mg, 0.703 mmol) and DIPEA (116 ⁇ l_, 0.675 mmol) in DMSO (3 ml_) was heated at 55 0 C for 24 h. The reaction was concentrated in vacuo and the residue purified by reverse phase preparative HPLC (Method 3) to afford the title compound (202 mg, 41%) as an off-white solid.
  • LCMS Methodhod 4: Rt 8.46 min, m/z 703 [MH + ].
  • Example 1 step b To a solution of Example 1 step b (300 mg, 0.67 mmol) in THF (5 mL) at O 0 C was added dropwise 2 M isopropylmagnesium chloride in Et 2 O (335 ⁇ l_, 0.67 mmol). The reaction was stirred at O 0 C for 1 h, then 2,2'-dithiobis(5-nitro- pyridine) (227 mg, 0.73 mmol) was added. The reaction was allowed to warm to RT and stirred for an additional 1 h then diluted with EtOAc (10 mL). The organic layer was washed with 1 M NaOH (10 mL), brine (10 mL), dried (MgSO 4 ), and concentrated in vacuo.
  • Example 12 step a (50 mg, 0.11 mmol) was dissolved in EtOH (10 ml.) and treated with Pd/C (10%) (10 mg). The reaction was stirred at RT under an atmosphere of hydrogen over 72 h. The catalyst was filtered under nitrogen and the filtrate concentrated in vacuo to give the title compound (31 mg, 66%).
  • Example 1 step b A mixture of Example 1 step b (234 mg, 0.52 mmol), copper (I) iodide (9 mg, 0.052 mmol), 1 ,10-phenanthroline (19 mg, 0.104 mmol), cesium carbonate (335 mg, 1.04 mmol) and frans ⁇ -boc-aminocyclohexanol (560 mg, 2.6 mmol) in toluene (3 ml_) was heated at 11O 0 C for 72 h under an argon atmosphere. The suspension was cooled to RT, diluted with EtOAc (10 ml.) and filtered through HiFIo.
  • Example 14 step a A solution of Example 14 step a (196 mg, 0.178 mmol) in TFA (2 mL) and DCM (10 mL) was stirred at RT for 0.5 h, then concentrated in vacuo to give the title compound (quantitative yield).
  • LCMS Method 2: Rt 0.38 min, m/z 438 [M- CF 3 CO 2 + ]. c.
  • Example 17 step a 32 mg, 0.076 mmol
  • Example 17 step b 23 mg, 0.076 mmol
  • potassium iodide 4 mg, 0.002 mmol
  • potassium carbonate 13 mg, 0.091 mmol
  • acetonitrile 5 mL
  • the reaction mixture was allowed to cool to RT, concentrated in vacuo and purified twice purified by reverse phase preparative HPLC (Method 6) to afford the title compound (5 mg, 9%) as a white solid.
  • LCMS Methodhod 4: ⁇ Rt 6.21 min, m/z 693 [MH + ].
  • Example 20 step a 80 mg, 0.12 mmol and triethylamine trihydrofluoride (40 mg, 0.24 mmol) in THF (2 mL) was stirred at RT for 24h, then diluted with EtOAc, washed with sat. aq. sodium bicarbonate, dried (Na 2 SO 4 ), and evaporated. The residue was purified by FCC (DCM/MeOH 100/0 to 95/5), dissolved in EtOAc, washed with aq. citric acid and brine, dried (Na 2 SO 4 ), evaporated and dried in vacuo at 4O 0 C to afford the title compound (45 mg, 68%) as a pink solid.
  • Example 21 step a A solution of Example 21 step a (0.41g, 2.08 mmol), triphenylphosphine (763 mg, 2.91 mmol) and triethylamine (0.87 ml_, 6.24 mmol) in THF (5 mL) at O 0 C was treated with 1 ,2-hexachloroethane (690 mg, 2.91 mmol).
  • Example 22 step a 50 mg, 0.145 mmol
  • 1 N sodium hydroxide 0.5 ml_, 0.5 mmol
  • MeOH 2 ml_
  • the reaction mixture was treated with sat. aq. sodium bicarbonate, evaporated to dryness, and purified on a reverse phase FCC (water/MeOH 100/.0 to 0/100) to give two fractions.
  • the first eluting fraction was acidified to pH 5 with 1 N HCI solution and extracted with EtOAc.
  • the organic layer was dried (MgSO 4 ), filtered, combined with the second eluting fraction from chromatography and concentrated in vacuo.
  • Example 23 step a (430 mg, 1.5 mmol), terf-butyl 2-(4- hydroxyphenyl)acetate (WO2008/024746, 621 mg, 3 mmol), cesium carbonate (978 mg, 3 mmol), copper (I) chloride (74 mg, 0.75 mmol) and 2,2,6,6- tetramethylheptanedione (28 mg, 0.15 mmol) in ⁇ /-methylpyrrolidinone (2 ml_) was heated at 115°C for 1 h. The reaction mixture was left to cool to RT, diluted with diethyl ether and washed with water.
  • Example 23 step b A solution of Example 23 step b (44 mg, 0.12 mmol), TFA (1 mL) and anisole (1 mL) in DCM (1 mL) was stirred at RT for 1 h, then evaporated in vacuo. The resulting residue was suspended in diethyl ether (3 mL), filtered and dried in vacuo to give the title compound (38 mg, quant.).
  • Example 28 was prepared using similar method to that used in Example 1.
  • LCMS (Method 11): Rt 5.12 min, m/z 525 [MH + ].
  • 1 H NMR 400 MHz, CDCI 3 ): ⁇ 1.36 (9H, s), 1.54 (6H, d, J 8Hz), 2.41 (3H, s), 3.37 (1 H, q, J 8Hz), 6.71 (1 H, s), 7.12-7.16 (1 H, m), 7.28-7.33 (2H, m), 7.35-7.46 (5H, m), 6.68-7.73 (1 H 1 m), 7.78 (1 H 1 S), 7.91 (1 H, s), 8.12 (1 H, s).
  • Example 29
  • Human recombinant p38 enzyme expressed in E. coli and activated by incubation with MKK6 enzyme (Calbiochem #559324) is used as source of enzyme activity.
  • the assay is carried in high binding, clear, flat bottom 96 well assay plates which have been coated with recombinant ATF-2 (Biosource #PHF0043). Test compounds are incubated with p38 kinase for 2h prior to initiating the kinase assay by the addition of ATP to obtain an assay concentration of 250 ⁇ M. Phosphorylation of ATF-2 is detected and quantified using an ELISA. This consists of sequential incubation in the presence of anti-phospho-ATF2, biotinylated anti-lgG and streptavidin-HRP. Incubation with an HRP chromogenic substrate (TMB) results in absorbance that is proportional to the amount of phosphorylated substrate produced. Absorbance is detected using a multiwell plate reader.
  • TMB HRP chromogenic substrate
  • Compounds are diluted in DMSO prior to addition to assay buffer, the final DMSO concentration in the assay being 1%.
  • the IC 50 is defined as the concentration at which a given compound achieves 50% inhibition of control. Results are shown in Table 1 : Table 1
  • p38 ⁇ binding potencies are indicated as follows: ⁇ 2000-500nM '+'; ⁇ 500-100nM '++'; 10 - ⁇ 100nM '+++'; ⁇ 10nM '++++'. All compounds tested exhibited IC 50 values ⁇ 2000nM; NT not tested. p38 functional assay
  • TNF ⁇ a functional response which is quantified by measurement of the amount of TNF ⁇ in the supernatants of LPS activated THP-1 cells (an immortalised monocytic cell line) or peripheral blood mononuclear cells (PBMCs) isolated from freshly drawn human blood.
  • LPS activated THP-1 cells an immortalised monocytic cell line
  • PBMCs peripheral blood mononuclear cells
  • EC 50 values are indicated as follows: ⁇ 7000-500nM '+'; ⁇ 500- 10OnM '++'; 10 - ⁇ 100nM '+++'; ⁇ 10nM '++++'. All compounds tested exhibited EC 50 values ⁇ 2000nM; NT not tested.
  • Biological assays are indicated as follows: ⁇ 7000-500nM '+'; ⁇ 500- 10OnM '++'; 10 - ⁇ 100nM '+++'; ⁇ 10nM '++++'. All compounds tested exhibited EC 50 values ⁇ 2000nM; NT not tested.
  • mice to TS obtaining bronchoalveolar lavage (BAL)
  • BAL bronchoalveolar lavage
  • cytospin slides for differential cell counts are as outlined below. Exposure of mice to TS daily for 4 or 11 consecutive days
  • mice were exposed in groups of 5 in individual clear polycarbonate chambers (27 cm x 16 cm x 12 cm).
  • the TS from the cigarettes was allowed to enter the exposure chambers at a flow rate of 100 ml/min.
  • the exposure of the mice to TS was increased gradually over the exposure period to a maximum of 6 cigarettes.
  • the exposure schedule used for 4 days was as follows:
  • the exposure schedule used for 11 days exposure was as follows:
  • mice were exposed to air on a daily basis for equivalent lengths of time as controls (no TS exposure).
  • Bronchoalveolar lavage was performed as follows: the trachea was cannulated using a Portex nylon intravenous cannula (pink luer fitting) shortened to approximately 8 mm. Phosphate buffered saline (PBS) was used as the lavage fluid. A volume of 0.4 ml was gently instilled and withdrawn 3 times using a 1ml syringe and then placed in an Eppendorf tube and kept on ice prior to subsequent determinations. Cell counts:
  • Lavage fluid was separated from cells by centrifugation and the supernatant decanted and frozen for subsequent analysis.
  • the cell pellet was re-suspended in a known volume of PBS and total cell numbers calculated by counting a stained (Turks stain) aliquot under a microscope using a haemocytometer.
  • the residual cell pellet was diluted to approximately 10 5 cells per ml. A volume of 500 ⁇ l was placed in the funnel of a cytospin slide and centrifuged for 8 min at 800 rpm. The slide was air dried and stained using 'Kwik-Diff solutions (Shandon) as per the proprietary instructions. When dried and cover-slipped, differential cells were counted using light microscopy. Up to 400 cells were counted by unbiased operator using light microscopy. Cells were differentiated using standard morphometric techniques. Drug Treatment
  • Rodents such as mice and rats are obligate nasal breathers thus oral delivery of test materials (such as therapeutic agents) for inhalation will not produce good lung exposure.
  • delivery of therapeutic agents to the lungs in rodents is generally achieved by intra-nasal, intra-tracheal or inhalation by whole body aerosol exposure in a chamber.
  • the chamber method utilises large amounts of test material and is generally reserved for inhalation toxicology studies rather than pharmacological efficacy studies.
  • Intra-tracheal administration is a very efficient delivery method as almost all of the test material is delivered to the lungs, but this is quite an invasive technique. For studies in the mouse particularly, it is also quite technically demanding as the diameter of the trachea is quite small.
  • the intranasal route is less invasive than the intra-tracheal route and so is particularly suitable for repeat dosing studies such as the 4-11 day mouse model described below. Following intranasal administration ⁇ 50% of the dose administered is delivered to the lungs (Eyles JE, Williamson ED and Alpar HO. 1999, lnt J Pharm, 189(1):75-9).
  • mice were dosed intra-nasally with vehicle (0.2% tween 80 in saline), Example 10 (30 ⁇ g/kg), Example 10 (100 ⁇ g/kg) or Example 10 (300 ⁇ g/kg).
  • vehicle 0.2% tween 80 in saline
  • Example 10 (30 ⁇ g/kg)
  • Example 10 100 ⁇ g/kg
  • Example 10 300 ⁇ g/kg
  • the control group of mice received vehicle 1 hr prior to being exposed to air daily for a maximum of 50 minutes per day.
  • TS exposure was conducted for 4 days.
  • BAL was performed 24 h following the final TS exposure.
  • Figure 1 is a bar graph that illustrates the effect of intranasal administration to laboratory mice with vehicle (0.2% tween 80 in saline), Example 10 (30 ⁇ g/kg), Example 10 (100 ⁇ g/kg) or Example 10 (300 ⁇ g/kg) on the number of BAL cells induced by tobacco smoke 24 hours post the final exposure.
  • Figure 2 is a bar graph that illustrates the effect of intranasal administration to laboratory mice with vehicle (0.2% tween 80 in saline), Example 10 (30 ⁇ g/kg), Example 10 (100 ⁇ g/kg) or Example 10 (300 ⁇ g/kg) on the number of BAL neutrophils induced by tobacco smoke 24 hours post the final exposure.
  • Example 10 significantly inhibited the BAL cell influx induced by TS at 30, 100 or 300 ⁇ g/kg when administered by the intranasal route. Similar findings were observed with BAL neutrophils ( Figure 2). The results demonstrate a clear anti-inflammatory effect in the lungs of mice exposed to TS.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract wherein; R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R3 and R4 are independently H or C1-C6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6- membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is -O- or -S(O)P- wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divale nt cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(=O)W-; W is a bond, -NH- or -C(RA)(RB), wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and R2 is a radical as defined in the claims.

Description

TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS
This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract. Background to the invention
Mitogen activated protein kinases (MAPK) constitute a family of proline- directed serine/threonine kinases that activate their substrates by dual phosphorylation. There are four known human isoforms of p38 MAP kinase, p38α, p38β, p38γ and p38δ. The p38 kinases, which are also known as cytokine suppressive anti-inflammatory drug binding proteins (CSBP), stress activated protein kinases (SAPK) and RK, are responsible for phosphorylating (Stein et al., Ann. Rep. Med Chem., 1996, 31 , 289-298) and activating transcription factors (such as ATF-2, MAX, CHOP and C/ERPb) as well as other kinases (such as MAPKAP-K2/3 or MK2/3), and are themselves activated by physical and chemical stress (e.g. UV, osmotic stress), pro-inflammatory cytokines and bacterial lipopolysaccharide (LPS) (Herlaar E. & Brown Z., Molecular Medicine Today, 1999, 5, 439-447). The products of p38 phosphorylation have been shown to mediate the production of inflammatory cytokines, including tumor necrosis factor alpha (TNF α) and interleukin- (IL-)-1 , and cyclooxygenase-2 (COX-2). IL-1 and TNFα are also known to stimulate the production of other proinflammatory cytokines such as IL-6 and IL-8.
IL-1 and TNFα are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation (e.g. Dinarello et ai, Rev. Infect. Disease, 1984, 6, 51). Excessive or unregulated TNF production (particularly TNFα) has been implicated in mediating or exacerbating a number of diseases, and it is believed that TNF can cause or contribute to the effects of inflammation in general. IL-8 is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL-1 , TNF, or lipopolysaccharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes and basophils. Increase in IL-8 production is also responsible for chemotaxis of neutrophils into the inflammatory site in vivo.
Inhibition of signal transduction via p38, which in addition to IL-1 , TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (e.g., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for p38 kinase inhibitors (Badger et al., J. Pharm. Exp. Thera., 1996, 279, 1453-1461 ; Griswold et al, Pharmacol. Comm.,1996, 7, 323-229). In particular, p38 kinase inhibitors have been described as potential agents for treating rheumatoid arthritis. In addition to the links between p38 activation and chronic inflammation and arthritis, there is also data implicating a role for p38 in the pathogenesis of airway diseases in particular COPD and asthma. Stress stimuli (including tobacco smoke, infections or oxidative products) can cause inflammation within the lung environment. Inhibitors of p38 have been shown to inhibit LPS and ovalbumin induced airway TNF-q IL-1 β, IL-6, IL-4, IL-5 and IL-13 (Haddad et al, Br. J. Pharmacol., 2001 , 132 (8), 1715-1724; Underwood et al, Am. J. Physiol. Lung Cell. MoI. 2000, 279, 895-902; Duan et al., 2005 Am. J. Respir. Crit. Care Med., 171 , 571-578; Escort et al Br. J. Pharmacol., 2000, 131 , 173-176; Underwood et al., J. Pharmacol. Exp. Ther. 2000, 293, 281-288). Furthermore, they significantly inhibit neutrophilia and the release of MMP-9 in LPS, ozone or cigarette smoke animal models. There is also a significant body of preclinical data highlighting the potential benefits of inhibition of the p38 kinase that could be relevant in the lung (Lee et al., Immunopharmacology, 2000, 47, 185-200). Thus, therapeutic inhibition of p38 activation may be important in the regulation of airway inflammation.
The implication of the p38MAPK pathway in various diseases has been reviewed by P. Chopra et al. (Expert Opinion on Investigational Drugs, 2008, 17(10), 1411-1425). It is believed that the compounds of the present invention can be used to treat p38 mediated diseases such as: asthma, chronic or acute bronchoconstriction, bronchitis, acute lung injury and bronchiectasis, pulmonary artery hypertension, tuberculosis, lung cancer, inflammation generally (e.g. inflammatory bowel disease), arthritis, neuroinflammation, pain, fever, fibrotic diseases, pulmonary disorders and diseases (e.g., hyperoxic alveolar injury), cardiovascular diseases, post-ischemic reperfusion injury and congestive heart failure, cardiomyopathy, stroke, ischemia, reperfusion injury, renal reperfusion injury, brain edema, neurotrauma and brain trauma, neurodegenerative disorders, central nervous system disorders, liver disease and nephritis, gastrointestinal conditions, ulcerative diseases, Crohn's disease, ophthalmic diseases, ophthalmological conditions, glaucoma, acute injury to the eye tissue and ocular traumas, diabetes, diabetic nephropathy, skin-related conditions, myalgias due to infection, influenza, endotoxic shock, toxic shock syndrome, autoimmune disease, graft rejection, bone resorption diseases, multiple sclerosis, psoriasis, eczema, disorders of the female reproductive system, pathological (but non-malignant) conditions, such as hemaginomas, angiofibroma of the nasopharynx, and avascular necrosis of bone, benign and malignant tumors/neoplasia including cancer, leukaemia, lymphoma, systemic lupus erthrematosis (SLE), angiogenesis including neoplasia, haemorrhage, coagulation, radiation damage, and/or metastasis. Chronic release of active TNF can cause cachexia and anorexia, and TNF can be lethal. TNF has also been implicated in infectious diseases. These include, for example, malaria, mycobacterial infection and meningitis. These also include viral infections, such as HIV, influenza virus, and herpes virus, including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella- zoster virus (VZV), Epstein-Barr virus, human herpes virus-6 (HHV-6), human herpesvirus-7 (HHV7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.
Known P38 kinase inhibitors have been reviewed by G. J. Hanson (Expert Opinions on Therapeutic Patents, 1997, 7, 729-733) J Hynes et al. (Current Topics in Medicinal Chemistry, 2005, 5, 967-985), C. Dominguez et al (Expert Opinions on Therapeutics Patents, 2005, 15, 801-816) and L. H. Pettus & R. P. Wurtz (Current Topics in Medicinal Chemistry, 2008, 8, 1452-1467). P38 kinase inhibitors containing a triazolopyridine motif are known in the art, for example WO07/091152, WO04/072072, WO06/018727. Summary of the Invention
The compounds of the present invention are inhibitors of p38 mitogen activated protein kinase ("p38 MAPK", "p38 kinase" or "p38"), including p38α kinase, and are inhibitors of cytokine and chemokine production including TNFα and IL-8 production. They have a number of therapeutic applications, in the treatment of inflammatory diseases, particularly allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases such as chronic obstructive pulmonary disease ("COPD") and asthma. They are therefore particularly suited for pulmonary delivery, by inhalation by nose or mouth.
According to the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
wherein;
R1 is CrC6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6-membered monocyclic heteroaryl which is optionally substituted or a radical of formula (II)
Figure imgf000005_0002
wherein n is 1 or 2; and R3 and R4 are independently H or CrC6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6- membered heterocyclic ring optionally containing a further heteroatom selected from N and O;
Y is -O- or -S(0)p- wherein p is O, 1 or 2;
A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divalent cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(=0)W-;
W is a bond, -NH- or -C(RA)(RB)-, wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and R2 is a radical of formula (IIIA), (IMB) or (NIC):
Figure imgf000006_0001
((HA) (HIB) (HIC)
wherein m is 0 or 1 ; q is 0, 1 , 2 or 3;
T is -N= or -CH=;
R5 is H or F;
R7 is -CH3, -C2H5, -CH2OH, -CH2SCH3, -SCH3 or -SC2H5;
R8 is -CH3 or -C2H5; and each occurrence of R6 is independently H, C1-C6 alkyl, hydroxy or halo; or a single occurrence of R6 is a radical of formula (IVA), (IVB) or (IVC)
Figure imgf000006_0002
(IVA) (IVB) (IVC) while any other occurrence of R6 is independently H, CrCε alkyl, hydroxyl or halo ; wherein n and p are as defined above; and wherein in R6
R61a and R61b are H, alkyl, or R61a and R61b may be joined together with the nitrogen to which they are attached to form a heterocyclic ring optionally containing a further heteroatom selected from N and O.
In another aspect, the invention includes pharmaceutical compositions comprising a compound of the invention, together with one or more pharmaceutically acceptable carriers and/or excipients. Particularly preferred are compositions adapted for inhalation for pulmonary administration. In another aspect, the invention includes the use of a compound of the invention for the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity. The treatment of obstructive or inflammatory airways diseases is a preferred use. All forms of obstructive or inflammatory airways diseases are potentially treatable with the compounds of the present invention, in particular an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic eosinophilic pneumonia, asthma, COPD, COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension, chronic inflammatory diseases including cystic fibrosis, broncietasis and pulmonary fibrosis (Idiopathic). Efficacy is anticipated when p38 kinase inhibitors are administered either locally to the lung (for example by inhalation and intranasal delivery) or via systemic routes (for example, oral, intravenous and subcutaneous delivery). Description of the invention Terminology
As used herein, the term "(Ca-Cb)alkyr wherein a and b are integers, refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n- hexyl.
As used herein, the term "carbocyclic" refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl.
As used herein, the term "cycloalkyl" refers to a monocyclic saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
The term "divalent cycloalkylene radical" refers to a cycloalkyl radical having two unsatisfied valencies such as 1 ,3-cyclopentylene and 1 ,4- cyclohexylene, as follows:
Figure imgf000008_0001
As used herein, the unqualified term "aryl" refers to a mono- or bi-cyclic carbocyclic aromatic radical, and includes radicals having two monocyclic carbocyclic aromatic rings which are directly linked by a covalent bond. Illustrative of such radicals are phenyl, biphenyl and napthyl.
The term "divalent arylene radical" refers to a monocyclic or bicyclic aryl radical having two unsatisfied valencies such as 1 ,3-phenylene or 1 ,4-phenylene as follows:
Figure imgf000008_0002
or 1 ,4-naphthalenyl as follows:
Figure imgf000008_0003
As used herein, the unqualified term "heteroaryl" refers to a mono- or bicyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, which are directly linked by a covalent bond. Illustrative examples of such radicals are thienyl, benzothienyl, furyl, benzofuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benzotriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
As used herein, the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in its non-aromatic meaning relates to a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzofuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
The term "divalent heteroarylene radical" refers to a monocyclic or bicyclic heteroaryl radical having two unsatisfied valencies such as the following:
Figure imgf000009_0001
with the folowing being currently preferred
Figure imgf000009_0002
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any aryl or heteroaryl moiety herein means substituted with at least one substituent, for example selected from (CrC6)alkyl, (CrCe) fluoroalkyl, (CrCεJalkoxy (including methylenedioxy and ethylenedioxy substitution on adjacent carbon atoms of an aromatic ring), (Ci-C6)fluoroalkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, benzyloxy-(CrC6)alkyl, (CrC6)alkoxy-(Ci-C6)alkoxy, benzyloxy-(Ci-C6)alkoxy, hydroxy, hydroxy(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, mercapto, mercapto(Ci-C6)alkyl, (d-C6)alkylthio, cyclopropyl, halo (including fluoro and chloro), O-benzyl, nitro, nitrile (cyano), -COOH, tetrazolyl, -COORA, -CORA, -SO2RA, -CONH2, -SO2NH2, -CONHRA, -SO2NHRA, -CONRARB, -SO2NRARB, -NH2, -NHRA, -NRARB, -OCONH2, -OCONHRA, -OCONRARB, -NHCORA, -NHCOORA, -NRBCOORA, -NHSO2ORA, -NRBSO2ORA, -NHCONH2, -NRACONH2, -NHCONHR6 -NRACONHRB, -NHCONRARB or -NRACONRARB wherein RA and RB are independently a (CrC4)alkyl group, or RΛ and RB when attached to the same nitrogen may form, together with that nitrogen, a cyclic amino group such as a morpholinyl, piperidinyl or piperazinyl group. An "optional substituent" may be one of the substituent groups encompassed in the above description.
Compounds of the invention may exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and frans-forms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers may be prepared by the application of adaptation of known methods (e.g. asymmetric synthesis).
As used herein the term "salt" includes base addition, acid addition and ammonium salts. As briefly mentioned above compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. Λ/-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, Λ/-ethyl piperidine, dibenzylamine and the like. Those compounds of the invention which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, trifluoroacetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like. Those compounds (I) which have a basic nitrogen can also form quaternary ammonium salts with a pharmaceutically acceptable counter-ion such as ammonium, chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi-succinate, naphthalene- bis sulfonate, methanesulfonate, trifluoroacetate, xinafoate, and the like. For a review on salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
It is expected that compounds of the invention may be prepared in the form of hydrates, and solvates. Any reference herein, including the claims herein, to "compounds with which the invention is concerned" or "compounds of the invention" or "the present compounds", and the like, includes reference to salts hydrates, and solvates of such compounds. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Individual compounds of the invention may exist in several polymorphic forms and may be obtained in different crystal habits.
The compounds may also be administered in the form of prodrugs thereof. Thus certain derivatives of the compounds which may be active in their own right or may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of the invention having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and V.J. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association; CS. Larsen and J. østergaard, Design and application of prodrugs, In Textbook of Drug Design and Discovery, 3rd Edition, 2002, Taylor and Francis).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985). Such examples could be a prodrug of a carboxyl group (such as -CO-O-CH2-O- CO-tBu as used in the pivampicillin prodrug of ampicillin), an amide (-CO-NH- CH2-NAIk2) or an amidine (-C(=N-O-CH3)-NH2).
In the compounds of the invention, the divalent radical -W-[A]-Y- may be, for example, any of the corresponding radicals in the specific Example compounds below. For example, that radical may be one of the following formulae (B) - (J):
Figure imgf000012_0001
(B) (C) (D) (E) (F)
Figure imgf000012_0002
(G) (H) (I) (J)
One subclass of compounds of the invention has formula (IA):
Figure imgf000012_0003
wherein V, V, X and X' are independently -CH= or -N=; and R1, R2, Y and W are as defined in relation to formula (I). Within this subclass, compounds may have formula (IA1):
Figure imgf000012_0004
wherein Y is O or S and R1 and R2 are as defined in relation to formula (I). Another subclass of compounds of the invention has formula (IB):
Figure imgf000012_0005
wherein U is CH or N, and R1, R2, Y and W are as defined in relation to formula (I), with the proviso that when U is N then W is not NH. Within this subclass, compounds may have formula (IB1):
Figure imgf000012_0006
wherein Y is O or S and R1 and R2 are as defined in relation to formula (I). A further subclass of compounds of the invention has formula (IC):
Figure imgf000013_0001
wherein Y is O or S, R2 is as defined in claim 1 , and R1 is phenyl, 5- or 6- membered monocyclic heteroaryl or a radical of formula (II) as defined in relation to formula (I) above.
In the compounds of the invention, including the subclasses of formulae (IA), (IA1), (IB), (IB1), and (IC) above, specific currently preferred structural features include the following:
R1 may be a group of formula (II) as defined in relation to formula (I) above wherein the group -NR3R4 is morpholinyl.
R1 may be isopropyl or 2,6-dichlorophenyl.
R2 may be a radical of formula (NIC) as defined in relation to formula (I) above, wherein R7 and R8 are each methyl.
R2 may have formula (HID), (HIE), (IMF) or (IMG):
Figure imgf000013_0002
R2 may be a radical of formula (I I IA) as defined in relation to formula (I), wherein m is 0.
R2 may be a radical of formula (MIB) as defined in relation to formula (I) above, wherein (a) T is -CH= and R5 = H; or (b) T is -N= and R5 = H; or (c) T - CH= and R5 = F. Optional substituents in the divalent radical A include -CN, -F, -Cl, -Br, -NO2, -OH, -SO2Ci-C2 alkyl, -SO2C1-C2 fully or partially fluorinated alkyl, C1-C4 alkyl, fully or partially fluorinated C1-C4 alkyl, C1-C4 alkoxy, fully or partially fluorinated C1-C4 BIkOXy, and -SCF3.
The divalent radical A may be a six-membered ring such as phenylene or pyridinylene, linked to Y and W in a 1 ,3 (meta) or 1 ,4 (para) orientation.
The divalent radical A may be a cyclohexylene radical linked to W and Y in a trans-1 ,4 orientation.
W may be -CH2-. Utility
As mentioned above the compounds of the invention are p38MAPK inhibitors, and thus may have utility for the treatment of diseases or conditions which benefit from inhibition of the p38 enzyme. Such diseases and conditions are known from the literature and several have been mentioned above. However, the compounds are generally of use as anti-inflammatory agents, particularly for use in the treatment of respiratory disease. In particular, the compounds may be used in the treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, or smoking-induced emphysema, intrinsic (non-allergic asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, steroid resistant asthma, neutrophilic asthma, bronchitic asthma, exercise induced asthma, occupational asthma and asthma induced following bacterial infection, cystic fibrosis, pulmonary fibrosis and bronchiectasis. Compositions
As mentioned above, the compounds with which the invention is concerned are p38 kinase inhibitors, and are useful in the treatment of several diseases for example inflammatory diseases of the respiratory tract. Examples of such diseases are referred to above, and include asthma, rhinitis, allergic airway syndrome, bronchitis and chronic obstructive pulmonary disease.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art. In general, the daily dose range for oral administration will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a human, often 0.01 mg to about 50 mg per kg, for example 0.1 to 10 mg per kg, in single or divided doses. In general, the daily dose range for inhaled administration will lie within the range of from about 0.1 μg to about 1mg per kg body weight of a human, preferably 0.1 μg to 50 μg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases. For the purpose of the invention, inhaled administration is preferred.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. Orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
However, for treatment of an inflammatory disease of the respiratory tract, compounds of the invention may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers. For delivery by inhalation, the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze- drying and micronisation. Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
By way of example, a composition of the invention may be prepared as a suspension for delivery from a nebuliser or as an aerosol in a liquid propellant, for example for use in a pressurised metered dose inhaler (PMDI). Propellants suitable for use in a PMDI are known to the skilled person, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (CCI2F2) and HFA-152 (CH4F2 and isobutane)
In a preferred embodiment of the invention, a composition of the invention is in dry powder form, for delivery using a dry powder inhaler (DPI). Many types of DPI are known.
Microparticles for delivery by administration may be formulated with excipients that aid delivery and release. For example, in a dry powder formulation, microparticles may be formulated with large carrier particles that aid flow from the DPI into the lung. Suitable carrier particles are known, and include lactose particles; they may have a mass median aerodynamic diameter of greater than 90 μm. In the case of an aerosol-based formulation, an example is:
Compound of the invention 24 mg / canister
Lecithin, NF Liq. Cone. 1.2 mg / canister
Trichlorofluoromethane, NF 4.025 g / canister
Dichiorodifluoromethane, NF 12.15 g / canister.
The active compounds may be dosed as described depending on the inhaler system used. In addition to the active compounds, the administration forms may additionally contain excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
For the purposes of inhalation, a large number of systems are available with which aerosols of optimum particle size can be generated and administered, using an inhalation technique which is appropriate for the patient. In addition to the use of adaptors (spacers, expanders) and pear-shaped containers (e.g. Nebulator®, Volumatic®), and automatic devices emitting a puffer spray (Autohaler®), for metered aerosols, in particular in the case of powder inhalers, a number of technical solutions are available (e.g. Diskhaler®, Rotadisk®, Turbohaler® or the inhalers for example as described EP-A-0505321). Additionally, compounds of the invention may be delivered in multi-chamber devices thus allowing for delivery of combination agents. Combinations
Other compounds may be combined with compounds with which the invention is concerned for the prevention and treatment of inflammatory diseases, in particular respiratory diseases. Thus the present invention is also concerned with pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents. Suitable therapeutic agents for a combination therapy with compounds of the invention include, but are not limited to: (1) corticosteroids, such as fluticasone propionate, fluticasone furoate, mometasone furoate, beclometasone dipropionate, ciclesonide, budesonide, GSK 685698, GSK 870086, QAE 397, QMF 149, TPI-1020; (2) β2-adrenoreceptor agonists such as salbutamol, albuterol, terbutaline, fenoterol, and long acting β2-adrenoreceptor agonists such as salmeterol, indacaterol, formoterol (including formoterol fumarate), arformoterol, carmoterol, GSK 642444, GSK 159797, GSK 159802, GSK 597501 , GSK 678007, AZD3199; (3) corticosteroid/long acting β2 agonist combination products such as salmeterol/fluticasone propionate (Advair/Seretide), formoterol/budesonide (Symbicort), formoterol/fluticasone propionate (Flutiform), formoterol/ciclesonide, formoterol/mometasone furoate, indacaterol/mometasone furoate, Indacaterol/QAE 397, GSK 159797/GSK 685698, GSK 159802/GSK 685698, GSK 642444/GSK 685698, GSK 159797/GSK 870086, GSK 159802/GSK 870086, GSK 642444/GSK 870086, arformoterol/ciclesonide;(4) anticholinergic agents, for example muscarinic-3 (M3) receptor antagonists such as ipratropium bromide, tiotropium bromide, Aclidinium (LAS-34273), NVA-237, GSK 233705, Darotropium, GSK 573719, GSK 961081 , QAT 370, QAX 028; (5) dual pharmacology M3-anticholinergic/β2- adrenoreceptor agonists such as GSK961081 ; (6) leukotriene modulators, for example leukotriene antagonists such as montelukast, zafirulast or pranlukast or leukotriene biosynthesis inhibitors such as Zileuton or BAY-1005, or LTB4 antagonists such as Amelubant, or FLAP inhibitors such as GSK 2190914, AM- 103; (7) phosphodiesterase-IV (PDE-IV) inhibitors (oral or inhaled), such as roflumilast, cilomilast, Oglemilast, ONO-6126, Tetomilast, Tofimilast, UK 500,001 , GSK 256066 ; (8) antihistamines, for example selective histamine-1 (H1) receptor antagonists, such as fexofenadine, citirizine, loratidine or astemizole or dual H1/H3 receptor antagonists such as GSK 835726, GSK 1004723; (9) antitussive agents, such as codeine or dextramorphan; (10) a mucolytic, for example N acetyl cysteine or fudostein; (11) a expectorant/mucokinetic modulator, for example ambroxol, hypertonic solutions (e.g. saline or mannitol) or surfactant; (12) a peptide mucolytic, for example recombinant human deoxyribonoclease I (dornase-alfa and rhDNase) or helicidin; (13) antibiotics, for example azithromycin, tobramycin and aztreonam;
(14) non-selective COX-1 / COX-2 inhibitors, such as ibuprofen or ketoprofen;
(15) COX-2 inhibitors, such as celecoxib and rofecoxib; (16) VLA-4 antagonists, such as those described in WO97/03094 and WO97/02289; (17) TACE inhibitors and TNF-α inhibitors, for example anti-TNF monoclonal antibodies, such as Remicade and CDP-870 and TNF receptor immunoglobulin molecules, such as Enbrel; (18) inhibitors of matrix metalloprotease, for example MMP-12; (19) human neutrophil elastase inhibitors, such as ONO-6818 or those described in WO2005/026124, WO2003/053930 and WO06/082412; (20) A2b antagonists such as those described in WO2002/42298; (21) modulators of chemokine receptor function, for example antagonists of CCR3 and CCR8; (22) compounds which modulate the action of other prostanoid receptors, for example a thromboxane A2 antagonist; DP1 antagonists such as MK-0524, CRTH2 antagonists such as ODC9101 and AZD1981 and mixed DP1/CRTH2 antagonists such as AMG 009; (23) PPAR agonists including PPAR alpha agonists (such as fenofibrate), PPAR delta agonists, PPAR gamma agonists such as Pioglitazone, Rosiglitazone and Balaglitazone; (24) methylxanthines such as theophylline or aminophyliine and methylxanthine/corticosteroid combinations such as theophylline/budesonide, theophylline/fluticasone propionate, theophylline/ciclesonide, theophylline/mometasone furoate and theophylline/beclometasone dipropionate; (25) A2a agonists such as those described in EP1052264 and EP1241176; (26) CXCR2 or IL-8 antagonists such as SCH 527123 or GSK 656933; (27) IL-R signalling modulators such as kineret and ACZ 885; (28) MCP-1 antagonists such as ABN-912. Methods of synthesis
Compounds of the invention may be prepared according to the routes illustrated in Schemes 1-6.
Scheme 1
Figure imgf000019_0001
Compounds of general formula (l-a) may be prepared from compounds of general formula (IX):
HO2C
(IX), wherein r is 0 or 1 , Y is S or O, and Ra is as defined for R1 in general formula (I), by reaction with an amine of general formula (X):
R13NH2 (X), wherein Rb is as defined for R2 in general formula (I).
Using a suitable coupling agent such as 2-(7-aza-1/-/-benzotriazole-1-yl)- 1 ,1 ,3,3-tetramethyluronium hexafluorophosphate, 1 -ethyl-3-(3'- dimethylaminopropyl) carbodiimide or dicyclohexylcarbodiimide in the presence of a base such as diisopropylethylamine or triethylamine. The reaction may take place in a suitable solvent such as dichloromethane, Λ/,Λ/-dimethylformamide or tetrahydrofuran at a range of temperatures, preferably at room temperature.
Alternatively, compounds of formula (l-a) may be prepared from compounds of general formula (IX) by reaction with a suitable halogenating agent wich as oxalyl chloride or thionyl chloride in the absence or presence of a solvent such as dichloromethane or Λ/,Λ/-dimethylformamide at a range of temperatures, preferably from room temperature to 1000C, followed by reaction with an amine of general formula (X), using a suitable base such as diisopropylethylamine, in a suitable sovent such as tetrahydrofuran at a range of temperatures, preferably from room temperature to 800C.
Compounds of general formula (IX) may be prepared from compounds of general formula (V):
Figure imgf000020_0001
wherein X is a suitable leaving group such as fluorine, bromide or iodide, by reaction with a compound of general formula (VIII):
ROX, ,YH
(VIII),
wherein R is H or alkyl, using a suitable calatyst such as copper (I) iodide, copper (I) chloride, palladium acetate, tetrakis(triphenylphosphine)palladium (0) or dichloro(1 ,1'-bis(diphenylphosphino)ferrocene)palladium (II), in the absence or the presence of a suitable ligand such as (2,9-dimethyl)-1 ,10-phenanthroline, proline, 1 ,2-cyclohexyldiamine or a phosphine, using a base such as cesium carbonate, potassium hydroxide, potassium carbonate or sodium terf-butoxide. The reaction may take place in a suitable solvent such as toluene, N- methylpyrrolidinone or Λ/,Λ/-dimethylformamide at a range of temperatures, preferably between 40 and 1500C; followed, if R is alkyl, by hydrolysis according to methods known to those skilled in the art.
Compounds of general formula (V) may be prepared from compounds of general formula (IV):
Figure imgf000021_0001
using a suitable oxidant such as chloramine T, lead tetracetate or phenyliodine(lll) diacetate, in a suitable solvent such as dichloromethane or ethanol at a range of temperatures, preferably between room temperature and 1000C.
Compounds of general formula (IV) may be prepared from compounds of general formula (II):
Figure imgf000021_0002
by reaction with an aldehyde of general formula (III):
R3CHO (III), in a suitable solvent such as ethanol or tetrahydrofuran at a range of temperatures, preferably between room temperature and 8O0C.
Alternatively, compounds of formula (IV) may be prepared from compounds of formula (II) by reaction with a compound of general formula (Vl): R3CO2H (VI), using a suitable acylating/dehyd rating agent such as triphenylphosphine/trichloroacetonitrile in the presence of a base such as diisopropylethylamine, in a suitable solvent such as dichloromethane or acetonitrile, at a range of temperatures, preferably between room temperature and 1500C.
Alternatively, compounds of formula (IV) may be prepared from compounds of formula (VII):
Figure imgf000022_0001
using a suitable dehydrating agent such as Burgess' reagent, triphenyl phosphine and hexachloroethane, phosphorus oxychloride, acetic acid or Mitsunobu conditions
(diethylazodicarboxylate/triphenylphosphine/trimethylsilylazide), in the absence or presence of a suitable solvent such as tetrahydrofuran, toluene or NMP, at a range of temperatures, preferably between room temperature and 1200C.
Compounds of general formula (VII) may be prepared from compounds of general formula (II) by reaction with a carboxylic acid of general formula (Vl), as described for the preparation of compounds of formula (l-a) from compounds of formula (IX). Scheme 2
Figure imgf000022_0002
Compounds of general formula (l-b) may be prepared from compounds of general formula (XII): H2N €fsxxi»
(XII), wherein Ra is as defined for R1 in general formula (I), by reaction with a compound of general formula (XIII):
Figure imgf000023_0001
wherein Rb is as defined for R2 in general formula (I), in a suitable solvent such as dimethyl sulfoxide, 1 ,4-dioxane or acetonitrile, in the presence of a base such as diisopropylethylamine at a range of temperatures, preferably between room temperature and 1000C.
Compounds of general formula (XIII) may be prepared from amines of general formula (X) according to known literature procedures (e.g. WO2006/009741 , EP1609789).
Alternatively compounds of general formula (l-b) may be prepared from compounds of general formula (XII) by reaction with an amine of general formula (X), using a suitable coupling agent such as phosgene, diphosgene or triphosgene, in a suitable solvent such as dichloromethane, toluene, tetrahydrofuran or acetonitrile, using a suitable base such as triethylamine, pyridine or diisopropylethylamine, at a range of temperatures preferably between O and 1000C.
Compounds of general formula (XII) may be prepared from compounds of general formula (V):
^86N' (V),
by reaction with a compound of general formula (Xl):
H2N
SH (Xi), using a suitable base such as cesium carbonate, potassium hydroxide, potassium carbonate or sodium tert-butoxide, in the absence or presence of a suitable calatyst such as copper (I) iodide or copper (I) bromide and a suitable ligand such as (2,9-dimethyl)-1 ,10-phenanthroline, proline or 1 ,2- cyclohexyldiamine. The reaction may take place in a suitable solvent such as toluene, Λ/-methylpyrrolidinone, methanol or Λ/,Λ/-dimethylformamide at a range of temperatures, preferably between 40 and 1500C. Scheme 3
Figure imgf000024_0001
(l-c)
Compounds of general formula (l-c) may be prepared from compounds of general formula (XVI):
Figure imgf000024_0002
by reaction with a compound of general formula (XIII) or (X), as described for the preparation of compounds of formula (l-b) from compounds of formula (XII).
Compounds of general formula (XVI) may be prepared from compounds of general formula (XV):
Figure imgf000024_0003
(XV) wherein Rc may be a suitable protecting group or H by deprotection according to methods known to those skilled in the art.
Compounds of general formula (XV) may be prepared from compounds of general formula (V):
Figure imgf000025_0001
by reaction with a compound of general formula (XIV):
RCHN OH
(XiV),
as described for the preparation of compounds of formula (XII) from compounds of formula (Xl). Scheme 4
Figure imgf000025_0002
(l-d)
Compounds of general formula (l-d) may be prepared from compounds of general formula (XIX):
Figure imgf000025_0003
by reaction with a compound of general formula (XIII) or (X), as described for the preparation of compounds of formula (l-b) from compounds of formula (XII). Compounds of general formula (XIX) may be prepared from compounds of general formula (XVIII):
Figure imgf000026_0001
(XVlIl)1
by reaction with a suitable reductive agent such as tin (II) chloride, iron or hydrogen gas in the presence of a catalyst such as palladium on charcoal, platinum oxide or Raney Nickel, in the presence or absence of acid such as hydrogen chloride or acetic acid, in a suitable solvent such as methanol, ethanol or ethyl acetate, at a range of temperatures, preferably between room temperature and 800C.
Alternatively compounds of general formula (XIX) may be prepared from compounds of general (V):
Figure imgf000026_0002
by reaction with a compound of general formula (XVII):
Figure imgf000026_0003
wherein Rd is H, with a suitable metallated species such as butyllithium, magnesium or i-propylmagnesium chloride, in a suitable solvent such as tetrahydrofuran or diethyl ether, at a range of temperatures, preferably between - 780C and room temperature.
Compounds of general formula (XVIII) may be prepared from compounds of general formula (V) by reaction with a compound of general formula (XVII), wherein Rd is O, as described for the preparation of compounds of general formula (XIX) from compounds of general formula (V). Scheme 5
Figure imgf000027_0001
(V) (XXI) (XXII)
Figure imgf000027_0002
Compounds of general formula (l-e) may be prepared from compounds of general formula (XXII):
Figure imgf000027_0003
by reaction with a compound of general formula (XXIII):
o
Cl
(XXIII),
using a suitable base such as diisopropylethyiamine, potassium carbonate, sodium carbonate or sodium hydride in the absence or presence of a suitable catalyst such as potassium iodide or sodium iodide, in a suitable solvent such as dichloromethane, tetrahydrofuran or acetonitrile, at a range of temperatures, preferably between room temperature and 800C.
Compounds of general formula (XXIII) may be prepared from amines of general formula (X), according to known literature procedures (e.g. Migliara et al. Farmaco (1992), 47(1), 111-19).
Compounds of general formula (XXII) may be prepared from compounds of general formula (XXI): Ra
^O
N"\
R"N
(XXI)
wherein Rc is a suitable protecting group, by deprotection according to methods known to those skilled in the art.
Compounds of general formula (XXI) may be prepared from compounds of general formula (V):
Figure imgf000028_0001
by reaction with a compound of general formula (XX):
R^N λ~OH
(XX),
as described for the preparation of compounds of formula (XII) from compounds of formula (Xl). Scheme 6
W
Figure imgf000028_0002
Compounds of general formula (l-f) may be prepared from compounds of general formula (XXVI):
Figure imgf000029_0001
by reaction with amines of formula (X) as described for the preparation of compounds of general formula (l-a) from compounds of general formula (IX).
Compounds of general formula (XXVI) may be prepared from compounds of general formula (XXV):
Figure imgf000029_0002
wherein R is alkyl, by deprotection according to methods known to those skilled in the art.
Compounds of general formula (XXV) may be prepared from compounds of general formula (XXIV):
Figure imgf000029_0003
by reaction with a compound of general formula (V), as described for the preparation of compounds of general formula (XII) from compounds of general formula (Xl). Scheme 7
Compounds of general formula (V) may be prepared as described in Chem. Soc.Jpn., 1980, 53, 2007-11.
Figure imgf000029_0004
Scheme 8
Figure imgf000030_0001
(IX) (XXVII) (XXVIII)
Figure imgf000030_0002
(1-9) (XXIX)
Compounds of general formula (l-g) may be prepared from compounds of general formula (XXIX):
Figure imgf000030_0003
by reaction with an amine of general formula (X):
RbNH2 (X), wherein Rb is as defined for R2 in general formula (I) as described above.
Compounds of general formula (XXIX) may be prepared from compounds of general formula (XXVIII):
Figure imgf000030_0004
wherein Rc is alkyl by deprotection according to methods known to those skilled in the art.
Compounds of general formula (XXVIII) may be prepared from compounds of general formula (XXVII):
Figure imgf000031_0001
(XXVI l)
by reaction with a suitable compound RdX (XXXI) using a suitable base such as lithium hexamethyldisilazide or sodium hydride in a suitable solvent such as tetrahydrofuran, DMF or diethyl ether, at a range of temperatures, preferably between room temperature and 8O0C.
Compounds of general formula (XXVII) may be prepared from compounds of general formula (IX):
Figure imgf000031_0002
wherein r is 1 , Y is S or O, and Ra is as defined for R1 in general formula (I) by reaction with an alcohol of general formula (XXX) according to methods known to those skilled in the art.
RCOH (XXX)
General experimental details
Abbreviations used in the experimental section: aq. = aqueous; DCM = dichloromethane; DIPEA = diisopropylethylamine; DMF = Λ/,Λ/-dimethylformamide; DMSO = dimethyl sulfoxide;
EDCI HCI = 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride; EtOAc = ethyl acetate; EtOH = ethanol;
FCC = flash column chromatography; h = hour; HATU = 2-(7-aza-1H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate;
HOBt = 1-hydroxy-benzotriazole;
HPLC = high performance liquid chromatography;
LCMS = liquid chromatography mass spectrometry;
MeCN = acetonitrile;
MeOH = methanol; min = minutes;
NMR = nuclear magnetic resonance;
RT = room temperature;
Rt = retention time; sat. = saturated;
SCX-2 = strong cation exchange chromatography;
TFA = trifluoroacetic acid; THF = tetrahydrofuran.
The nomenclature of structures was assigned using Autonom 2000 Name software from MDL Inc.
All reactions were carried out under an atmosphere of nitrogen unless specified otherwise.
NMR spectra were obtained on a Varian Unity Inova 400 spectrometer with a 5mm inverse detection triple resonance probe operating at 400 MHz or on a Bruker Avance DRX 400 spectrometer with a 5 mm inverse detection triple resonance TXI probe operating at 400 MHz or on a Bruker Avance DPX 300 spectrometer with a standard 5 mm dual frequency probe operating at 300 MHz. Shifts are given in ppm relative to tetramethylsilane. NMR spectra were assigned using DataChord Spectrum Analyst Version 4.0.b21.
Where products were purified by flash column chromatography, 'flash silica' refers to silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Fluka silica gel 60), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution or use of the CombiFlash ® Companion purification system or use of the Biotage SP1 purification system. All solvents and commercial reagents were used as received.
Compounds purified by preparative HPLC were purified using a C18- reverse-phase column (100 * 22.5 mm i.d Genesis column with 7 μm particle size), or a Phenyl-Hexyl column (250 x 21.2 mm i.d. Gemini column with 5 μm particle size), UV detection at 230 or 254 nm, flow 5-20 mL/min), eluting with gradients from 100-0 to 0-100% water/acetonitrile (containing 0.1% TFA or 0.1% formic acid) or water/MeOH (containing 0.1% TFA or 0.1 % formic acid). Fractions containing the required product (identified by LCMS analysis) were pooled, the organic fraction removed by evaporation, and the remaining aqueous fraction lyophilised, to give the final product. Products purified by preparative HPLC were isolated as formate or TFA salts, unless otherwise stated.
The Liquid Chromatography Mass Spectroscopy (LCMS) and HPLC systems used are: Method 1
Waters ZMD quadrupole mass spectrometer with a C18-reverse-phase column (30 * 4.6 mm Phenomenex Luna 3 μm particle size), elution with A: water + 0.1 % formic acid; B: acetonitrile + 0.1 % formic acid. Gradient:
Gradient - Time flow mL/min %A %B
0.00 2.0 95 5
0.50 2.0 95 5
4.50 2.0 5 95
5.50 2.0 5 95
6.00 2.0 95 5
Detection - MS, ELS, UV (200 μL split to MS with in-line UV detector). MS ionization method - Electrospray (positive and negative ion).
Method 2
Waters Platform LC Quadrupole mass spectrometer with a C18-reverse-phase column (30 * 4.6 mm Phenomenex Luna 3 μm particle size), elution with A: water + 0.1 % formic acid; B: acetonitrile + 0.1% formic acid. Gradient:
Gradient - Time flow mLΛnin %A %B
0.00 2.0 95 5
0.50 2.0 95 5
4.50 2.0 5 95
5.50 2.0 5 95
6.00 2.0 95 5
Detection - MS, ELS, UV (200 μL split to MS with in-line UV detector). MS ionization method - Electrospray (positive and negative ion). Method 3
Phenomenex Gemini C18-reverse-phase column (250 * 21.20 mm 5 μm particle size), elution with A: water + 0.1% formic acid; B: acetonitrile + 0.1 % formic acid. Gradient - 95% A/5% B to 5% A/95% B over 15 min - flow rate 18 ml_/min. Detection - In-line UV detector set at 220 nM wavelength. Method 4
Waters Micromass ZQ2000 with a C18-reverse-phase column (100 * 3.0 mm Higgins Clipeus with 5 μm particle size), elution with A: water + 0.1% formic acid; B: acetonitrile + 0.1% formic acid. Gradient: Gradient - Time flow mL/min %A %B 0.00 1.0 95 5 1.00 1.0 95 5 15.00 1.0 5 95 20.00 1.0 5 95 22.00 1.0 95 5 25.00 1.0 95 5
Detection - MS, ELS, UV (100 μL split to MS with in-line UV detector). MS ionisation method - Electrospray (positive ion). Method 5
Waters Platform LC Quadrupole mass spectrometer with a C18-reverse- phase column (30 * 4.6 mm Phenomenex Luna 3 μm particle size), elution with A: water + 0.1 % formic acid; B: methanol + 0.1 % formic acid. Gradient: Gradient - Time flow mL/min %A %B 0.00 2.0 95 5 0.50 2.0 95 5 4.50 2.0 5 95 5.50 2.0 5 95 6.00 2.0 95 5
Detection - MS, ELS, UV (200 μL split to MS with in-line HP1100 DAD detector). MS ionization method - Electrospray (positive and negative ion).
Method 6
Phenomenex Gemini C18-reverse-phase column (250 x 21.20 mm 5 μm particle size), elution with A: water + 0.1 % formic acid; B: methanol + 0.1% formic acid. Gradient - 95% A/5% B to 5% A/95% B over 15 min - flow rate 18 mL/min. Detection - In-line UV detector set at 254 nM wavelength. Method 7
Waters Micromass ZQ2000 with a C18-reverse-phase column (100 * 3.0 mm Higgins Clipeus with 5 μm particle size), elution with A: water + 0.1% formic acid; B: methanol + 0.1 % formic acid. Gradient: Gradient - Time flow mLΛnin %A %B 0.00 1.0 85 15 1.00 1.0 85 15 13.00 1.0 5 95 20.00 1.0 5 95 22.00 1.0 85 15 25.00 1.0 85 15
Detection - MS, ELS, UV (100 μL split to MS with in-line UV detector). MS ionisation method - Electrospray (positive ion). Method 8
Waters ZMD quadrupole mass spectrometer with a C18-reverse-phase column (30 x 4.6 mm Phenomenex Luna 3 μm particle size), elution with A: water + 0.1 % formic acid; B: methanol + 0.1 % formic acid. Gradient: Gradient - Time flow mLΛnin %A %B 0.00 2.0 95 5 0.50 2.0 95 5 4.50 2.0 5 95 5.50 2.0 5 95 6.00 2.0 95 5
Detection - MS, ELS, UV (200 μL split to MS with in-line Waters 996 DAD detector). MS ionization method - Electrospray (positive and negative ion). Method 9
Waters Micromass ZQ2000 with a Acquity BEH C18 column (50 x 2.1 mm with 1.7 μm particle size), elution with A: water + 0.1 % formic acid; B: methanol + 0.1 % formic acid. Gradient:
Gradient - Time flow ml_/mιn %A %B
0.00 0.4 85 15
0.40 0.4 85 15
6.00 0.4 5 95
8.00 0.4 5 95 8.80 0.4 85 15
10.00 0.4 85 15
Detection - MS, UV PDA. MS ionisation method - Electrospray (positive/negative ion).
Method 10
Waters Quatro Microtriple quadrupole with a C18-reverse-phase column (100 x 3.0 mm Higgins Clipeus with 5 μm particle size), elution with A: water + 0.1 % formic acid; B: methanol + 0.1 % formic acid. Gradient: Gradient - Time flow mL/min %A %B 0.00 1.0 85 15 1.00 1.0 85 15 13.00 1.0 5 95 20.00 1.0 5 95 22.00 1.0 85 15 25.00 1.0 85 15
Detection - MS, ELS, UV (100 μl_ split to MS with in-line UV detector). MS ionisation method - Electrospray (positive/negative ion). Method 11
Waters ZMD quadrupole mass spectrometer with a C18-reverse-phase column (Acquity BEH C18 reverse column, 1.7um, 100 x 2.1 mm), elution with A: water + 0.1 % formic acid; B: acetonitrile + 0.1% formic acid. Gradient:
Gradient - Time flow mL/min %A %B
0.00 0.4 95 5
0.40 0.4 95 5
6.00 0.4 5 95
6.80 0.4 5 95
7.00 0.4 95 5
8.00 0.4 95 5
Detection - MS, UV PDA. MS ionisation method - Electrospray (positive/negative ion). Example 1
Λ/-Cyclopropylmethyl-3-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-
[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-benzamide
Figure imgf000037_0001
a. Λ/-(5-lodo-pyridin-2-yI)-Λ/'-[1-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-meth- (E)-ylidene]-hydrazine
Figure imgf000037_0002
To a suspension of 5-iodo-2-hydrazinopyιϊdine (6.62 g, 0.028 mmol) in EtOH (90 ml_) was added 3-(2-morpholin-4-yl-ethoxy)-benzaldehyde (6.63 g, 0.028 mmol). The reaction was heated at reflux for 2 h under nitrogen, then cooled to RT. The resulting precipitate was collected by filtration and washed with EtOH to afford the title compound (10.93 g, 86%) as a white solid. LCMS (Method 1): Rt 2.37 min, m/z 453 [MH+]. 1H NMR (300 MHz, CD3OD): δ 8.24 (1 H, d, J 2.2), 7.90-7.84 (2 H, m), 7.36-7.18 (3 H, m), 7.12 (1 H, d, J 8.8), 6.94- 6.89 (1 H, m), 4.19 (2 H, t, J 5.4), 3.72 (4 H1 1, J 4.6), 2.83 (2 H, t, J 5.4), 2.62 (4 H, t, J 4.6). b. 6-lodo-3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3- a]pyridine
Figure imgf000037_0003
To a solution of Example 1 step a (10.93 g, 24.16 mmol) in DCM (100 ml_)/EtOH (15 ml_), was added PhI(OAc)2 (10.74 g, 33.35 mmol). The reaction was stirred at RT for 72 h, diluted with DCM (25 ml_) then washed with aq. sodium hydroxide (1 M, 25 ml.) and brine (25 ml_). The organic layer was dried (MgSO4), filtered, and the filtrate was concentrated in vacuo. The residue was triturated with Et2O (10 ml_) and the resulting solid was collected by filtration to afford the title compound (9.98 g, 92%) as an off-white solid. LCMS (Method 1): Rt 2.11 min, m/z 451 [MH+]. 1H NMR (400 MHz, DMSO-d6): δ 8.69 (1 H, s), 7.71 (1 H, d, J 9.5), 7.60 (1 H, d, J 9.5), 7.53 (1 H, t, J 7.9), 7.47-7.41 (2 H, m), 7.18 (1 H, d, J 8.1), 4.21 (2 H, t, J 5.7), 3.59 (4 H, t, J 4.5), 2.75 (2 H, t, J 5.7), 2.45 (4 H, m). c. 3-{3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6- ylsulfanylj-benzoic acid
Figure imgf000038_0001
A reaction vessel was charged with Example 1 step b (400 mg, 0.888 mmol), 3-mercaptobenzoic acid (205 mg, 1.24 mmol), [1 ,1'- bis(diphenylphosphino)ferrocene] dichloropalladium(ll) 1 :1 complex with DCM (138 mg, 0.168 mmol), cesium carbonate (578 mg, 1.777 mmol), and DMF (3 ml_). The reaction was degassed (x3) under argon. The reaction was heated at 9O0C for 24 h then allowed to cool to RT, filtered, and the filtrate concentrated in vacuo to afford the title compound (422 mg, quantitative). LCMS (Method 2): Rt 2.20 min, m/z 477 [MH+]. d. /V-Cyclopropylmethyl-3-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-[1,2,4] triazolo[4,3-a]pyridin-6-ylsulfanyl}-benzamide
A reaction vessel was charged with Example 1 step c (213 mg, 0.447 mmol), cyclopropanemethylamine (32 mg, 0.447 mmol), HATU (212 mg, 0.558 mmol), and DMF (3 ml_). DIPEA (225 μl_, 1.34 mmol) was added, the reaction was stirred at RT for 24 h then concentrated in vacuo and the crude residue purified directly by reverse phase preparative HPLC (Method 3) to afford the title compound (92 mg, 39%) as an off-white solid. LCMS (Method 4): Rt 6.55 min, m/z 530 [MH+]. 1H NMR (400 MHz, CDCI3): δ 8.39 (1 H, s), 7.89 (1 H, s), 7.75- 7.65 (2 H, m), 7.51-7.30 (5 H, m), 7.17 (1 H, d, J 9.6), 7.08 (1 H, d, J 8.4), 6.85 (1 H, m), 4.25 (2 H, t, J 5.2), 3.79 (4 H, t, J 4.4), 3.26 (2 H, t, J 6.2), 3.00 (2 H, t, J 5.2), 2.77 (4 H, m), 1.07-0.95 (1 H, m), 0.52-0.44 (2 H, m), 0.24-0.18 (2 H, m).
The following Examples were prepared using similar methods to that used in Example 1. Example Structure NMR (400 MHz) δ LCMS No.
(CDCI3): 8.63 (1 H, s), 8.35 (1 H, s), 8.00 (1 H, s), 7.82 (1 H, d, J
7.5), 7.54 (1 H, d, J 9.5), 7.50-
7.40 (4 H, m), 7.34-7.28 (2 H, (Method 3): Rt m), 7.18 (1 H, t, J 8.1), 7.14-7.03
(2 H, m), 6.99 (1 H, d, J 8), 6.66 7.15 min, m/z
Figure imgf000039_0001
(1 H, dd, J 8.3, 2.4), 4.16 (2 H, t, 637 [MH+].
J 5.6), 3.79 (4 H, t, J 4.6), 3.73 (4
H, t, J 4.6), 3.11 (4 H, t, J 4.7),
2.85 (2 H, t, J 5.5), 2.60 (4 H, t, J
4.4).
(CDCI3): 8.80 (1 H, br s), 8.39 (1
H, t, J 1.2), 8.07 (1 H, d, J 5.7),
7.97 (1 H, t, J 1.7), 7.81 (1 H, dt,
J 7.6, 1.5), 7.59 (1 H, dd, J 9.5, (Method 4)- Rt
1), 7.55-7.44 (3 H, m), 7.40-7.32
(3 H, m), 7.16 (1 H, dd, J 1.6, 5-49 mιn. m/z
Figure imgf000039_0002
0.3), 7.10 (1 H, dd, J 2.6, 1 ), 6.75 638 [MH +]
(1 H, dd, J 5.7, 1.7), 4.24 (2 H, t,
J 5.3), 3.78 (8 H, m), 3.49 (4 H, t,
J 4.8), 2.97 (2 H, t, J 5.3), 2.75 (4
H, t, J 4.5)
(CDCI3): 8.41 (1 H, s), 7.75 (1 H, d, J 9.6), 7.49 (1 H, t, J 8), 7.40
(1 H, s), 7.35 (1 H, d, J 7.7), 7.26 (Method 4): Rt
(2 H, d, J 5.5), 7.19-7.10 (5 H, m), 7.13-7.05 (4 H, m), 6.59 (1 8-32 min. m/z
Figure imgf000039_0003
H, s), 4.25 (2 H, t, J 5.5), 3.79 (4 702 [MH+]
H, t, J 4.5), 3.65 (2 H, s), 2.93 (2
H, t, J 5.5), 2.70 (4 H, t, J 4.3),
2.37 (3 H, s), 1.32 (9 H, s).
(CDCI3): 8.39 (1 H, s), 7.69 (1 H,
O d, J 9.5), 7.47 (1 H, t, J 8), 7.37-
Cr0 7.25 (7 H, m), 7.17 (1 H, d, J (Method 3): Rt
9.7), 7.07 (2 H, m), 6.69 (1 H, d, 7 59 min m/z
J 10), 6.29 (1 H, d, 11.8), 4.18 (2
H, t, J 5.2), 3.79-3.71 (8 H, m), [MH I 669-
3.69 (2 H, s), 3.08 (4 H, t, J 4.5),
2.85 (2 H, t, J 5.5), 2.61 (4 H, m).
(CD3OD): 8.50 (1 H, s), 7.64 (1
H, d, J 9.6), 7.32 (2 H, d, J 8.1), (Method 4): Rt
7.28 (1 H, dd, J 9.6, 1.6), 7.21-
7.15 (6 H, m), 6.30 (1 H, s), 3.57 1 1 -35 mιn< m/z
(2 H, s), 3.53 (1 H, m), 2.32 (3 H, 539 rMH +]
S), 1.47 (3 H, s), 1.45 (3 H, s),
1.30 (9 H, s).
(CD3OD): 7.89 (1 H, s), 7.84 (1
H, dd, J 9.6, 1.0), 7.64-7.53 (3 H, (Method 4)- Rt m), 7.43 (1 H, dd, J 9.6, 1.6),
7.35-7.28 (2 H, m), 7.22-7.15 (2 12-70 mιn> m/z
H, m), 7.15 (4 H, s), 6.32 (1 H, 641 [MH +]
Figure imgf000039_0004
s), 3.57 (2 H, S), 2.31 (3 H, s),
1.31 (9 H, s). (CD3OD): 8.26 (1 H, t, J 1.2), 7.75-7.68 (1 H, m), 7.48 (1 H, t, J (Method 7): Rt
8.0), 7.44 (2 H, d, J 7.5), 7.40 (1 H, t, J 2.0), 7.38-7.25 (7 H, m), 13.44 min, m/z 7.22-7.08 (7 H, m), 6.32 (1 H, s),
Figure imgf000040_0001
679 [MH+]. 5.13 (2 H, s), 3.53 (2 H, s), 2.29 (3 H, s), 1.38-1.20 (9 H, m).
(CDCI3): 8.07 (1 H, s), 7.68 (1 H, d, J 9.6), 7.33 (3 H, m), 7.29- 7.13 (5 H, m), 7.07 (2 H, dd, J (Method 9): Rt 9.5, 1.7), 6.59 (1 H, s), 3.80-3.59 4.11 min, m/z (6 H, m), 3.52 (2 H, m), 3.41-
Figure imgf000040_0002
3.30 (1 H, m), 2.47 (4 H, m), 624 [MH+]. 1.55 (3 H, s), 1.53 (3 H, s), 1.32 (9 H, s).
Example 10
1-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-phenyl)-urea
Figure imgf000040_0003
a. 3-(6-Bromo-[1 ,2,4]triazolo[4,3-a]pyridin-3-yl)-phenol
Figure imgf000040_0004
Boron tribromide (1 M in DCM, 13.1 ml_, 13.1 mmol) was added slowly to a stirred solution of S-^-benzyloxy-phenyO-δ-bromo-π ^^triazolo^.S-alpyridine (1 g, 2.63 mmol) in DCM (5 ml_) at -780C. The reaction was allowed to warm up to RT, stirred for 24 h, and treated with sat. NaHCO3 solution until pH > 7. The product was extracted with DCM:MeOH 9:1 (ml_) , dried (MgSO4), and concentrated in vacuo. Purification of the crude residue by FCC (DCM:MeOH, 1 :0 to 9:1 ) afforded the title compound (350 mg, 46%) as a yellow solid. LCMS (Method 2): Rt 2.65 min, m/z 290 and 292 [MH+]. b. 6-Bromo-3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-[1 ,2,4]triazolo[4,3- ajpyridine
Figure imgf000041_0001
A mixture of Example 10 step a (250 mg, 1.21 mmol), Λ/-(2- bromoethyl)morpholine hydrochloride (306 mg, 1.32 mmol) and K2CO3 (500 mg, 3.62 mmol) in DMF (20 ml_) was heated at 5O0C for 24 h. The reaction was then allowed to cool to RT and concentrated in vacuo. The residue was purified by FCC (DCM:MeOH, 1 :0 to 9:1) to afford the title compound (479 mg, 98%) as a yellow oil. 1H NMR (300 MHz1CDCI3): δ 8.44 (1 H, dd, J 1.7, 1), 7.74-7.69 (1 H, m), 7.50 (1 H, t, J 7.9), 7.39-7.35 (2 H, m), 7.35-7.30 (1 H, m), 7.14-7.08 (1 H, m), 4.21 (2 H, t, J 5.6), 3.74 (4 H, t, J 4.6), 2.85 (2 H, t, J 5.6), 2.63-2.56 (4 H, m). c. 4-{3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6- ylsulfanylj-phenylamine
Figure imgf000041_0002
The title compound was prepared in a similar manner to Example 1 step c using Example 10 step b and 4-amino-benzene-thiol. LCMS (Method 2): Rt 2.14 min, m/z 448 [MH+]. d. 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-phenyl)-urea
A mixture of Example 10 step c (315 mg, 0.703 mmol), 5-(2,2,2- trichloroethoxycarbonyl)amino-3-ferf-butyl-1-p-tolyl-1/-/-pyrazole (299 mg, 0.703 mmol) and DIPEA (116 μl_, 0.675 mmol) in DMSO (3 ml_) was heated at 550C for 24 h. The reaction was concentrated in vacuo and the residue purified by reverse phase preparative HPLC (Method 3) to afford the title compound (202 mg, 41%) as an off-white solid. LCMS (Method 4): Rt 8.46 min, m/z 703 [MH+]. 1H NMR (400 MHz1CDCI3): δ 9.30 (1 H, br s), 8.34 (1 H, br s), 8.16 (1 H, s), 7.49-7.41 (3 H, m), 7.37 (1 H, d, J 9.6), 7.29 (2 H, d, J 8.4), 7.25-7.20 (2 H, m), 7.18 (2 H, d, J 8), 7.09-7.04 (2 H, m), 6.90 (2 H, d, J 8), 6.44 (1 H, s), 4.15 (2 H, t, J 5.4), 3.72 (4 H, t, J 4.5), 2.88 (2 H, t, J 5.4), 2.64 (4 H, t, J 4.4), 2.11 (3 H, s), 1.30 (9 H, s). The following Example was prepared using similar methods to those used in Example 10 (steps c-d) :
Example Structure NMR (400 MHz) δ LCMS No.
(CDCI3) 942 (1 H, bs),
(Method 4) Rt 13 95 mm, m/z 680 [MH+]
Figure imgf000042_0001
Example 12
1-(5-tert-ButyI-2-p-tolyI-2H-pyrazol-3-yl)-3-(6-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-pyridin-3-yl)-urea
Figure imgf000042_0002
a. 3-[3-(2-Λflorpholin-4-yl-ethoxy)-phenyl]-6-(5-nitro-pyridin-2-ylsulfanyl)- [1 ,2,4]triazolo[4,3-a]pyridine
Figure imgf000042_0003
To a solution of Example 1 step b (300 mg, 0.67 mmol) in THF (5 mL) at O0C was added dropwise 2 M isopropylmagnesium chloride in Et2O (335 μl_, 0.67 mmol). The reaction was stirred at O0C for 1 h, then 2,2'-dithiobis(5-nitro- pyridine) (227 mg, 0.73 mmol) was added. The reaction was allowed to warm to RT and stirred for an additional 1 h then diluted with EtOAc (10 mL). The organic layer was washed with 1 M NaOH (10 mL), brine (10 mL), dried (MgSO4), and concentrated in vacuo. Purification by reverse phase preparative HPLC (Method 3) afforded the title compound (50 mg, 16%) as a yellow solid. LCMS (Method 1): Rt 2.33 min, m/z 479 [MH+]. 1H NMR (400 MHz, CD3OD): δ
9.16 (1 H, d, J 2.6), 8.80 (1 H, t, J 1.2), 8.41 (1 H, dd, J 8.9, 2.7), 7.90 (1 H, dd, J
9.6, 1), 7.60-7.53 (2 H, m), 7.50-7.45 (3 H, m), 7.25-7.20 (1 H, m), 4.27 (2 H, t, J
5.4), 3.73 (4 H, t, J 4.7), 2.94 (2 H, t, J 5.4), 2.70 (4 H, t, J 4.5). b. 6-{3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6- ylsulfanyl}-pyridin-3-ylamine
Figure imgf000043_0001
Example 12 step a (50 mg, 0.11 mmol) was dissolved in EtOH (10 ml.) and treated with Pd/C (10%) (10 mg). The reaction was stirred at RT under an atmosphere of hydrogen over 72 h. The catalyst was filtered under nitrogen and the filtrate concentrated in vacuo to give the title compound (31 mg, 66%). LCMS (Method 1): Rt 1.94 min, m/z 449 [MH+]. c. 1-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(6-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-pyridin-3-yl)-urea
The title compound was prepared in a similar manner to Example 10 step d using Example 12 step b. LCMS (Method 4): Rt 8.06 min, m/z 704 [MH+]. 1H NMR (400 MHz1CDCI3): δ 8.70 (1 H, br s), 8.57 (1 H, s), 8.25 (1 H, dd, J 8.7, 2.7), 7.99 (1 H, d, J 2.7), 7.73 (1 H, br s), 7.63 (1 H, d, J 9.5), 7.47 (1 H, t, J 8), 7.35-7.23 (6 H, m), 7.09 (1 H, dd, J 8.4, 2.5), 7.04 (2 H, d, J 8), 6.45 (1 H, s), 4.20 (2 H, t, J 5.4), 3.73 (4 H, t, J 4.6), 2.91 (2 H, t, J 5.4), 2.67 (4 H, s), 2.22 (3 H, s), 1.34 (9 H, s).
Example 13
1-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yI)-3-(5-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-pyridin-2-yl)-urea
Figure imgf000043_0002
a. 5-{3-[3-(2-Morpholin-4-yI-ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6- ylsulfanyl}-pyridin-2-ylamine
χysτr«
Figure imgf000044_0001
The title compound was prepared in a similar manner to Example 1 step c using 2-amino-5-mercaptopyridine dihydrochloride. LCMS (Method 1): Rt 1.77 min, m/z 449 [MH+]. b. 1-(5-ferf-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(5-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl}-pyridin-2-yl)-urea
The title compound was prepared in a similar manner to Example 10 step d using Example 13 step a. LCMS (Method 4): Rt 8.25 min, m/z 704 [MH+]. 1H NMR (400 MHz, CD3OD): δ 8.31 (1 H, s), 7.84 (1 H, dd, J 8.7, 2.4), 7.81-7.77 (1 H, m), 7.74 (1 H, d, J 2.4), 7.55 (1 H, t, J 7.9), 7.41-7.33 (5 H, m), 7.30 (2 H, d, J 8.1), 7.22 (1 H, dd, J 8.4, 2.4), 7.03 (1 H, d, J 8.6), 6.51 (1 H, s), 4.26 (2 H, t, J 5.4), 3.75 (4 H, t, J 4.6), 2.97 (2 H, t, J 5.4), 2.74 (4 H, t, J 4.6), 2.26 (3 H, s), 1.34 (9 H, s).
Example 14
1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(frans-4-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-cyclohexyl)-urea
Figure imgf000044_0002
a. (frans-4-{3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3- a]pyridin-6-yloxy}-cyclohexyl)-carbamic acid ferf-butyl ester
Figure imgf000044_0003
A mixture of Example 1 step b (234 mg, 0.52 mmol), copper (I) iodide (9 mg, 0.052 mmol), 1 ,10-phenanthroline (19 mg, 0.104 mmol), cesium carbonate (335 mg, 1.04 mmol) and frans^-boc-aminocyclohexanol (560 mg, 2.6 mmol) in toluene (3 ml_) was heated at 11O0C for 72 h under an argon atmosphere. The suspension was cooled to RT, diluted with EtOAc (10 ml.) and filtered through HiFIo. The filtrate was concentrated in vacuo and the residue purified by reverse phase preparative HPLC (Method 3) to afford the title compound (205 mg, 39%) as an off-white solid. LCMS (Method 2): Rt 2.53 min, m/z 538 [MH+]. b. frans-4-{3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-[1,2,43triazolo[4,3- a]pyridin-6-yloxy}-cyclohexylamine trifluoroacetic acid salt
Figure imgf000045_0001
A solution of Example 14 step a (196 mg, 0.178 mmol) in TFA (2 mL) and DCM (10 mL) was stirred at RT for 0.5 h, then concentrated in vacuo to give the title compound (quantitative yield). LCMS (Method 2): Rt 0.38 min, m/z 438 [M- CF3CO2 +]. c. 1-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(frans-4-{3-[3-(2-morpholin-4- yl-ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-cyclohexyI)-urea
The title compound was prepared in a similar manner to Example 10 step d using Example 14 step b. LCMS (Method 4): Rt 7.84 min, m/z 693 [MH+]. 1H NMR (400 MHz, CDCI3): δ 7.76 (1 H, d, J 2), 7.61 (1 H, d, J 9.9), 7.47 (1 H, t, J 8.1), 7.34-7.27 (4 H, m), 7.13 (2 H, d, J 8.1), 7.10-7.03 (2 H, m), 6.86 (1 H, s), 6.28 (1 H, s), 5.49 (1 H, d, J 7.6), 4.19 (2 H, t, J 5.4), 4.06-3.97 (1 H, m), 3.76- 3.67 (5 H, m), 2.88 (2 H, t, J 5.4), 2.62 (4 H, t, J 4.4), 2.29 (3 H, s), 2.07 (4 H, d, J 11.4), 1.65-1.53 (2 H, m), 1.33 (9 H, s), 1.29-1.16 (2 H1 m).
The following Examples were prepared using similar methods to that used in Example 14: Example Structure NMR (400 MHz) δ LCMS No.
15
min,
16
Figure imgf000046_0001
Example 17
/V-(5-fe/f-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-piperidin-1-yl)- acetamide
Figure imgf000046_0002
a. 3-[3-(2-Morpholin-4-yl-ethoxy)-phenyl]-6-(piperidin-4-yloxy)-
[1 ,2,4]triazolo[4,3-a]pyridine
Figure imgf000046_0003
The title compound was prepared in a similar manner to Example 14 steps a-b, using Λ/-Boc-4-hydroxypiperidine, followed by purification on SCX-2 cartridge. LCMS (Method 5): Rt 0.38, 1.87 min, m/z 424 [MH+]. b. Λ/-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-chloro-acetamide
Figure imgf000047_0001
A solution of 5-ferf-butyl-2-p-tolyl-2/-/-pyrazol-3-ylamine (886 mg, 3.86 mmol), pyridine (465 μL, 5.80 mmol) and chloroacetyl chloride (462 μl_, 5.80 mmol) in DCM (5 ml_) was stirred at RT for 2 h. The reaction mixture was diluted with aq. sat. sodium bicarbonate and DCM and the resulting aqueous layer was extracted twice with DCM. The combined organic layers were dried (MgSO4) and concentrated in vacuo to afford the title compound (1.17g, 100%) as a yellow solid. LCMS (Method 5): Rt 4.41 min, m/z 306 [MH+]. c. W-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-(4-{3-[3-(2-morpholin-4-yl- ethoxy)-phenyl]-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy}-piperidin-1-yl)- acetamide
A solution of Example 17 step a (32 mg, 0.076 mmol), Example 17 step b (23 mg, 0.076 mmol), potassium iodide (4 mg, 0.002 mmol) and potassium carbonate (13 mg, 0.091 mmol) in acetonitrile (5 mL) was heated to reflux for 2.5 h. The reaction mixture was allowed to cool to RT, concentrated in vacuo and purified twice purified by reverse phase preparative HPLC (Method 6) to afford the title compound (5 mg, 9%) as a white solid. LCMS (Method 4): δ Rt 6.21 min, m/z 693 [MH+]. 1H NMR (400 MHz, CD3OD): 7.92 (1 H, d, J 2.0), 7.76 (1 H, d, J 9.9), 7.58 (1 H, t, J 8.1), 7.43-7.32 (7 H, m), 7.22 (1 H, dd, J 8.4, 2.3), 6.51 (1 H, s), 4.36-4.29 (1 H, m), 4.26 (2 H1 1, J 5.4), 3.72 (4 H, t, J 4.6), 3.10 (2 H, s), 2.89 (2 H, t, J 5.4), 2.72-2.62 (6 H, m), 2.44-2.32 (5 H, m), 1.85 (2 H, m), 1.61-1.53 (2 H, m), 1.33 (9 H, s).
Example 18
W-(5-fert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-{4-[3-(3-hydroxy-phenyl)- [1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl]-phenyl}-acetamide
Figure imgf000048_0001
The title compound was prepared in a similar manner to Example 10 step a using Example 8. LCMS (Method 7): Rt 12.01 min, m/z 589 [MH+]. 1H NMR (400 MHz, CD3OD): δ 8.35 (1 H, t, J 1.2), 7.74 (1 H, dd, J 9.6, 1.0), 7.45-7.36 (1 H, m), 7.37-7.32 (3 H, m), 7.24-7.20 (4 H, m), 7.25-7.07 (4 H, m), 6.99 (1 H, ddd, J 8.2, 2.4, 1.1), 6.32 (1 H, s), 3.58 (2 H, s), 2.31 (3 H, s), 1.31 (9 H, s).
Example 19
Λ/-{5-fe/t-Butyl-2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-2-[4- (3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acetamide
Figure imgf000048_0002
a. 5-fert-Butyl-2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-ylamine
Figure imgf000048_0003
A solution of 4-(5-amino-3-tert-butyl-pyrazol-1-yl)-phenol
(WO2005/110994, 0.462 g, 2 mmol), 2-morpholin-4-yl-ethanol (0.327 g, 2.5 mmol) and triphenylphosphine (1.05 g, 4 mmol) in THF (5 ml_) under a nitrogen atmosphere was treated with diisopropyl azodicarboxylate (0.808 mg, 4 mmol). The reaction mixture was stirred at RT for 16h, then diluted with diethyl ether. The organic layer was washed with water. The resulting aqueous layer was basified with potassium carbonate and extracted with EtOAc. The resulting organic layer was washed with aq. citric acid solution, and the resulting aqueous layer was basified with potassium carbonate, and extracted with EtOAc (three times). The resulting organic layer was dried (Na2SO4), evaporated to dryness then sonicated with diethyl ether (10 mL) and filtered to give the title compound (0.297 g, 43%) as a white solid. LCMS (Method 5): Rt 0.41 , 2.16 min, m/z 345 [MH+]. 1H NMR (400 MHz, CDCI3): δ 7.46-7.39 (2 H, m), 6.98-6.93 (2 H, m), 5.50 (1 H, s), 4.15-4.08 (2 H, m), 3.75 (4 H, t, J 4.5), 3.63 (2 H, bs), 2.83-2.78 (2 H, m), 2.59 (4 H, t, J 4.3), 1.34-1.26 (9 H, m). b. Λ/-{5-te/t-Butyl-2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-2- [4-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsuIfanyl)-phenyl]-acetamide The title compound was prepared in a similar manner to Example 1 steps c-d, using 3-mercaptoacetic acid and Example 19 step a. LCMS (Method 7): Rt 9.09 min, m/z 654 [MH+]. 1H NMR (400 MHz, CDCI3): 8.12 (1 H, s), 7.70 (1 H, d, J 9.6), 7.22 (2 H, d, J 8.0), 7.20-7.09 (5 H, m), 7.12-7.05 (1 H, m), 6.93-6.86 (2 H, m), 6.57 (1 H, s), 4.17 (2 H, t, J 5.7), 3.73 (4 H, t, J 4.5), 3.64 (2 H, s), 3.41- 3.32 (1 H, m), 2.84 (2 H, t, J 5.7), 2.59 (4 H, t, J 4.4), 1.56 (3 H, s), 1.54 (3 H, s), 1.32 (9 H, s).
Example 20
/V-[5-fert-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(3-isopropyl- [1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acetamide
Figure imgf000049_0001
a. Λ/-{5-tert-Butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2H-pyrazol-3- yl}-2-[4-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]- acetamide
Figure imgf000050_0001
The title compound was prepared in a similar manner to Example 19 step b, using 5-te/ϊ-butyl-2-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2/-/-pyrazol-3- ylamine (US2006/035922). LCMS (Method 5): Rt 4.96 min, m/z 655 [MH+]. 1H NMR (300 MHz, CD3OD): δ 8.47 (1 H, s), 7.65 (1 H, dd, J = 9.60, 1.01 Hz), 7.35- 7.24 (3 H, m), 7.22-7.17 (4 H, m), 6.89-6.84 (2 H, m), 6.30 (1 H, s), 3.59 (2 H, s), 2.99 (1 H, m), 1.48 (3 H, s), 1.45 (3 H, s), 1.30 (9 H, s), 0.99 (9 H, s), 0.20 (6 H, s). b. Λ/-[5-terf-Butyl-2-(4-hydroxy-phenyl)-2H-pyrazol-3-yl]-2-[4-(3-isopropyl-
[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acetamide
A solution of Example 20 step a (80 mg, 0.12 mmol) and triethylamine trihydrofluoride (40 mg, 0.24 mmol) in THF (2 mL) was stirred at RT for 24h, then diluted with EtOAc, washed with sat. aq. sodium bicarbonate, dried (Na2SO4), and evaporated. The residue was purified by FCC (DCM/MeOH 100/0 to 95/5), dissolved in EtOAc, washed with aq. citric acid and brine, dried (Na2SO4), evaporated and dried in vacuo at 4O0C to afford the title compound (45 mg, 68%) as a pink solid. LCMS (Method 7): Rt 11.15 min, m/z 541 [MH+]. 1H NMR (400 MHz, CDCI3): δ 8.23 (1 H, s), 7.91 (1 H, s), 7.74 (1 H, d, J 9.5), 7.25-7.14 (5 H, m), 7.05 (2 H, d, J 8.4), 6.85 (2 H, t, J 8.6), 6.51 (1 H, s), 3.64 (2 H, s), 3.47-3.38 (1 H, m), 1.55 (3 H, s), 1.53 (3 H, s), 1.31 (9 H, s).
Example 21
1-(5-fert-Butyl-2-p-toIyI-2H-pyrazol-3-yl)-3-[4-(3-isopropyl-[1 ,2,4]triazolo[4,3- a]pyridin-6-yloxy)-cyclohexyl]-urea
Figure imgf000051_0001
a. lsobutyric acid W-(5-fluoro-pyridin-2-yl)-hydrazide
Figure imgf000051_0002
A solution of 5-fluoro-2-hydrazinyl-pyridine (0.59 g, 4.65 mmol), isobutyric acid (528 mg, 6 mmol), and HOBt hydrate (153 mg, 1 mmol) in DCM (10 ml.) was treated with EDCI HCI (1.15 g, 6 mmol). The reaction mixture was stirred at RT for 40 min, poured onto sat. aq. sodium bicarbonate (40 ml_), extracted with four portions of DCM, dried (Na2SO4), evaporated and purified by FCC (DCM/EtOAc 9/1 to 3/7) to give the title compound (0.42 g, 46%). LCMS (Method 8): Rt 2.46 min, m/z 198 [MH+]. b. 6-Fluoro-3-isopropyl-[1 ,2,4]triazolo[4,3-a]pyridine
Figure imgf000051_0003
A solution of Example 21 step a (0.41g, 2.08 mmol), triphenylphosphine (763 mg, 2.91 mmol) and triethylamine (0.87 ml_, 6.24 mmol) in THF (5 mL) at O0C was treated with 1 ,2-hexachloroethane (690 mg, 2.91 mmol). The reaction mixture was stirred at 0°C for 40 min then at RT for 20 min, quenched with water, extracted twice with EtOAc, dried (Na2SO4), evaporated and purified twice by FCC (cyclohexane/EtOAc 1/0 to 1/1) to afford the title compound (274 mg, contaminated with 20% PPh3O, 58%) as a white solid. LCMS (Method 5): Rt 2.58 min, m/z 180 [MH+]. c. 4-(3-lsopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexylamine
Figure imgf000051_0004
A solution of trans-4-amino-cyclohexanol (402 mg, 3.6 mmol) and potassium te/f-butoxide (395 mg, 3.6 mmol) in toluene (1 mL) and 1 ,3-dimethyl- 3,4,5,6-tetrahydro-2(1H)-pyrimidinone (0.5 mL) was heated at 800C under argon for 20 min, then treated with Example 21 step b (274 mg, contaminated with 20 % PPh3O, 1.2 mmol). The reaction mixture was stirred for 1 h, quenched with water and extracted with three portions of EtOAc. The aqueous and the combined organic layers were purified on SCX cartridge (MeOH to 1 N NH3 in MeOH), and the resulting residue was purified by FCC (DCM/MeOH with 0.1% NH3 100/0 to 85/15) to give the title compound (235 mg, 71%). LCMS (Method 5): Rt 1.86 min, m/z 275 [MH+]. d. 1 -(5-terf-Butyl-2-p-tolyI-2H-pyrazol-3-yl)-3-[4-(3-isopropyl-
[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-urea
The title compound was prepared in a similar manner to Example 10 step d starting from Example 21 step c and using dioxane in place of DMSO. LCMS (Method 7): Rt 11.66 min, m/z 530 [MH+]. 1H NMR (400 MHz, CDCI3): δ 7.60 (1 H, d, J 9.9), 7.37 (1 H, s), 7.34 (2 H, d, J 8.2), 7.19 (2 H, d, J 8.1), 7.03 (1 H, dd, J 9.9, 2.0), 6.37 (1 H, s), 6.23 (1 H, s), 5.12 (1 H, d, J 7.5), 4.07 (1 H, m), 3.73 (1 H, m), 3.31-3.22 (1 H, m), 2.34 (3 H, s), 2.12-2.05 (4 H, m), 1.68-1.56 (2 H, m), 1.51 (3 H, s), 1.49 (3 H, s), 1.54-1.31 (2 H, m), 1.34 (9 H, s). Example 22
W-(5-fert-Butyl-2-p-toiyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl-[1,2,4]triazolo[4,3- a]pyridin-6-yloxy)-cyclohexyl]-acetamide
Figure imgf000052_0001
a. [4-(3-lsopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-acetic acid ethyl ester
Figure imgf000052_0002
The title compound was prepared in a similar manner to Example 21 step c starting from frans-(4-hydroxy-cyclohexyl)-acetic acid ethyl ester (Krieg et a/., Journal fuer Praktische Chemie 1987, 329 (6), 1123-30)). LCMS (Method 5): Rt
4.16-4.23 min, m/z 346 [MH+]. b. [4-(3-lsopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-acetic acid
HO IXfXXf
A solution of Example 22 step a (50 mg, 0.145 mmol) and 1 N sodium hydroxide (0.5 ml_, 0.5 mmol) in MeOH (2 ml_) was stirred at RT for 16h. The reaction mixture was treated with sat. aq. sodium bicarbonate, evaporated to dryness, and purified on a reverse phase FCC (water/MeOH 100/.0 to 0/100) to give two fractions. The first eluting fraction was acidified to pH 5 with 1 N HCI solution and extracted with EtOAc. The organic layer was dried (MgSO4), filtered, combined with the second eluting fraction from chromatography and concentrated in vacuo. The resulting residue was dissolved in MeOH/EtOAc (1 :1 , 10 ml_), filtered and evaporated to dryness to give the title compound as a pale brown solid (27 mg, 59%). LCMS (Method 5): Rt 3.58-3.65 min, m/z 318 [MH+]. c. tø-(5-terf-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl-
[i^^triazolo^.S-aJpyridin-β-yloxyJ-cyclohexyll-acetamide
The title compound was prepared in a similar manner to Example 1 step d starting from Example 22 step b. LCMS (Method 10): Rt 11.59 min, m/z 529 [MH+]. 1H NMR (400 MHz, CDCI3): δ 7.67 (1 H, d, J 9.9), 7.38 (1 H, s), 7.36-7.25 (4 H, m), 7.20 (1 H, m), 7.04 (1 H, dd, J 9.8, 2.0), 6.60 (1 H, s), 4.10-3.98 (1 H, m), 3.3.28 (1 H, m), 2.41 (3 H, s), 2.21 (2 H, d, J 6.5), 2.16 (3 H, m), 1.93 (4 H, m), 1.52 (3 H, s), 1.51 (3 H, s), 1.34 (9 H, s), 1.23-1.07 (2 H, m). Example 23
Λ/-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl-[1,2,4]triazolo[4,3- a]pyridin-6-yloxy)-phenyl]-acetamide
Figure imgf000053_0001
a. 6-lodo-3-isopropyl-[1 ,2,4]triazolo[4,3-a]pyridine
Figure imgf000054_0001
The title compound was prepared in a similar manner to Example 1 steps a-b using 2-methyl-propionaldehyde. LCMS (Method 5): Rt 3.43 min, m/z 288 [MH+]. 1H NMR (300 MHz, CD3OD): 8.75 (1 H, s), 7.58 (1 H, dd, J 9.6, 1.5), 7.52 (1 H, dd, J 9.6, 1.1), 3.68-3.49 (1 H, m), 1.50 (3 H, s), 1.47 (3 H, s). b. 2-[4-(3-lsopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-phenyl]-acetamide
Figure imgf000054_0002
A solution of Example 23 step a (430 mg, 1.5 mmol), terf-butyl 2-(4- hydroxyphenyl)acetate (WO2008/024746, 621 mg, 3 mmol), cesium carbonate (978 mg, 3 mmol), copper (I) chloride (74 mg, 0.75 mmol) and 2,2,6,6- tetramethylheptanedione (28 mg, 0.15 mmol) in Λ/-methylpyrrolidinone (2 ml_) was heated at 115°C for 1 h. The reaction mixture was left to cool to RT, diluted with diethyl ether and washed with water. The aqueous layer was extracted with EtOAc and DCM and the combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The resulting oil was purified on a SCX-2 cartridge eluting with EtOAc, MeOH then 1 N ammonia in MeOH. The ammonia fractions were concentrated in vacuo and purified twice by FCC (DCM/MeOH containing NH3 10/0 to 9/1 then EtOAc) to provide the title compound as an orange gum (44 mg, 8%). LCMS (Method 8): Rt 4.30 min, m/z 368 [MH+]. c. [4-(3-lsopropyl-[1 ,2,4]trϊazolo[4,3-a]pyridin-6-yloxy)-phenyl]-acetic acid
Figure imgf000054_0003
A solution of Example 23 step b (44 mg, 0.12 mmol), TFA (1 mL) and anisole (1 mL) in DCM (1 mL) was stirred at RT for 1 h, then evaporated in vacuo. The resulting residue was suspended in diethyl ether (3 mL), filtered and dried in vacuo to give the title compound (38 mg, quant.). LCMS (Method 5): Rt 3.65 min, m/z 312 [MH+]. d. W-(5-te/t-ButyI-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl-
[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-phenyl]-acetamide
The title compound was prepared in a similar manner to Example 1 step d starting from Example 23 step c. LCMS (Method 10): Rt 11.60 min, m/z 523 [MH+]. 1H NMR (400 MHz, CDCI3): 7.77 (1 H, d, J 9.9), 7.66 (1 H, s), 7.29 (1 H, s), 7.26-7.15 (4 H, m), 7.14 (2 H, d, J 8.1 ), 7.05 (1 H, dd, J 9.9, 2.0), 6.98 (2 H, d, J 8.1 ), 6.60 (1 H, s), 3.67 (2 H, s), 3.27 (1 H, m), 2.39 (3 H, s), 1.52 (3 H, s), 1.50 (3 H, s), 1.33 (9 H, s).
Example 24
W-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl-[1,2,4]triazolo[4,3- a]pyridin-6-ylsulfanyl)-phenyl]-propionamide
Figure imgf000055_0001
a. [4-(3-Isopropyl-[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acetic acid methyl ester
Figure imgf000055_0002
To a solution of 4-(3-isopropyl-[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)- phenyl]-acetic acid (prepared in a similar manner to Example 1 step c) (209 mg, 0.639 mmol) in MeOH (20 ml_) was added concentrated HCI (25 μl_) and the reaction stirred at reflux for 5 h. The reaction was cooled to RT, concentrated in vacuo, partitioned between DCM (5 ml_) and sat. NaHCO3 (5 ml_), the organic layer was separated, dried (MgSO4), and concentrated in vacuo to afford the title compound (218 mg). LCMS (Method 1): Rt 3.04 min, m/z 342 [MH+]. b. 2-[4-(3-lsopropyl-[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]- propionic acid methyl ester
Figure imgf000056_0001
A solution of the product from Example 24 step b (218 mg, 0.637 mmol) in THF (5 ml.) was cooled to O0C and LiHMDS (1 M in hexanes, 702 μl, 0.702 mmol) was added. After 10 min. iodomethane (43 μl_, 0.702 mmol) was added and stirring continued at O0C for 0.5 h, then slowly allowed to warm to RT with stirring overnight. The reaction was quenched with sat. NH4CI solution (5 mL), extracted with Et2O (2 x 10 mL), dried (MgSO4), and concentrated in vacuo. Purification by chromatography using 0-10% DCM/MeOH gave the title compound (69.2 mg, 30%). LCMS (Method 1): Rt 3.25 min, m/z 356 [MH+]. c. 2-[4-(3-lsopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]- propionic acid
Figure imgf000056_0002
A solution of the product from Example 24 step c (69.2 mg, 0.194 mmol) in
1 M NaOH (1 mL) and MeOH (2 mL) was stirred at room temperature for 3.5 h. The reaction was quenched with acetic acid (1 mL) and concentrated in vacuo to afford the title compound. LCMS (Method 1): Rt 3.11 min, m/z 342 [MH+]. d. Λ/-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-2-[4-(3-isopropyl- [1,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-propionamide
The title compound was prepared in a similar manner to Example 1 step d starting from Example 24 step c. LCMS (Method 4): Rt 5.25 min, m/z 553 [MH+]. 1H NMR (400 MHz, MeOD): δ 8.53 (1 H, dd, J 1.6, 1.0Hz), 7.66 (1 H, dd, J 9.5, 1.0Hz), 7.34 (2 H, m), 7.31 (1 H, dd, J 9.5, 1.6Hz), 7.23 (2 H, m), 7.09 (4 H, s), 6.27 (1 H, s), 3.72 (1 H, q, J 7.1 Hz), 3.55 (1 H, m), 2.31 (3 H, s), 1.47 (6 H,
2 x d, J 6.9Hz), 1.40 (3 H, d, J 7.1 Hz), 1.30 (9 H, s). Example 25 i^δ-tert-Butyl^-p-tolyl^H-pyrazol-S-ylJ-S-^-tS-cyclopentyl- [1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-urea
Figure imgf000057_0001
The title compound was prepared in a similar manner to Example 21. LCMS (Method 1 1): Rt 4.59 min, m/z 555 [M+]. 1H NMR (400 MHz, MeOD): δ 7.88 (1 H, dd, J 2.1 , 0.8), 7.60 (1 H, dd, J 9.9, 0.8), 7.30 (4 H, m), 7.25 (1 H, dd, 9.9, 2.1), 6.27 (1 H, s), 4.32 (1 H, m), 3.57 (2 H, m), 2.38 (3 H, s), 2.20 (2 H, m), 2.10 (2 H, m), 1.87 (9 H, m), 1.56 (2 H, m), 1.35 (1 H, m), 1.28 (9 H, s).
Example 26
Figure imgf000057_0002
1 -[4-(3-lsopropyl-[1 ,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-3-[5-(1 - methyl-1-methylsulfanyl-ethyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea
The title compound was prepared in a similar manner to Example 1 step d starting from Example 21 step c. LCMS (Method 1 1): Rt 4.59 min, m/z 561 [M+]. 1H NMR (400 MHz, MeOD): δ 7.85 (1 H, dd, J 2.1 , 0.8), 7.57 (1 H, dd, J 9.9, 0.8), 7.30 (4 H, m), 7.21 (1 H, dd, 9.9, 2.1), 6.41 (1 H, s), 4.32 (1 H, m), 3.56 (1 H, m), (1 H, sept., J 6.9), 2.38 (3 H, s), 2.11 (2 H, m), 1.98 (2 H, m), 1.91 (3 H, s), 1.61 (6 H, s), 1.56 (2 H, m), 1 .42 (6 H, d, J 6.9), 1.35 (3 H, m). Example 27
N-{5-tert-Butyl-2-[3-(2-pyridin-4-yl-ethoxy)-phenyl]-2H-pyrazol-3-yl}-2-[4-(3- isopropyl-[1 ,2,4]triazolo[4,3-a]pyridin-6-ylsulfanyl)-phenyl]-acetamide
Figure imgf000058_0001
The title compound was prepared in a similar manner to Example 1 step d. LCMS (Method 11): Rt 3.81 min, m/z 646 [MH+]. 1H NMR (400 MHz, CDCI3): δ 8.53-8.49 (2 H1 m), 8.04 (1 H, s), 7.64 (1 H, d, J 9.6), 7.26 (1 H, s NH), 7.24-7.10 (7 H1 m), 7.02 (1 H, dd, J 9.6, 1.6), 6.87 (1 H, t, J 2.4), 6.82 (1 H, ddd, J 8.4, 2.4, 1.0), 6.63 (1 H, d, J 7.9), 6.57 (1 H, s), 4.19 (2 H, t, J 6.4), 3.62 (2 H, s), 2.36- 3.28 (1 H, m), 3.08 (2 H, t, J 6.4), 1.51 (6 H, d, 6.9), 1.29 (9 H, s). Example 28
Figure imgf000058_0002
Example 28 was prepared using similar method to that used in Example 1. LCMS (Method 11): Rt 5.12 min, m/z 525 [MH+]. 1H NMR (400 MHz, CDCI3): δ 1.36 (9H, s), 1.54 (6H, d, J 8Hz), 2.41 (3H, s), 3.37 (1 H, q, J 8Hz), 6.71 (1 H, s), 7.12-7.16 (1 H, m), 7.28-7.33 (2H, m), 7.35-7.46 (5H, m), 6.68-7.73 (1 H1 m), 7.78 (1 H1 S), 7.91 (1 H, s), 8.12 (1 H, s). Example 29
1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(3-pyridin-2-yl- [1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-cyclohexyl]-urea
Figure imgf000058_0003
The title compound was prepared in a similar manner to Example 10 step d using dioxane in place of DMSO and heating at 800C. LCMS (Method 7): Rt 4.95 min, m/z 565 [MH+]. 1H NMR (400 MHz, DMSO): δ. 9.36 (1 H, dd, J 2.3, 0.8), 8.74 (1 H, ddd, J 4.9, 1.8, 1.1), 8.34 (1 H, dt, J 8.1 , 1.1 , 1.1), 8.03-7.97 (1 H, m), 7.91 (1 H, s, NH), 7.86 (1 H, dd, J 9.8, 0.8), 7.48 (1 H, ddd, J 7.5, 4.9, 1.1), 7.37 (1 H, dd, J 9.8, 2.3), 7.31-7.24 (4 H, m), 6.52 (1 H, d, J 7.4 NH), 6.21 (1 H, s), 4.34-4.24 (1 H, m), 3.52-3.40 (1 H, m), 2.32 (3 H, s), 2.12-2.00 (2 H, m), 1.92- 1.84 (2 H, m), 1.56-1.44 (2 H, m), 1.34-1.22 (2 H, m), 1.20 (9 H, s). Biological assays p38 Kinase Assay
Human recombinant p38 enzyme expressed in E. coli and activated by incubation with MKK6 enzyme (Calbiochem #559324) is used as source of enzyme activity.
The assay is carried in high binding, clear, flat bottom 96 well assay plates which have been coated with recombinant ATF-2 (Biosource #PHF0043). Test compounds are incubated with p38 kinase for 2h prior to initiating the kinase assay by the addition of ATP to obtain an assay concentration of 250μM. Phosphorylation of ATF-2 is detected and quantified using an ELISA. This consists of sequential incubation in the presence of anti-phospho-ATF2, biotinylated anti-lgG and streptavidin-HRP. Incubation with an HRP chromogenic substrate (TMB) results in absorbance that is proportional to the amount of phosphorylated substrate produced. Absorbance is detected using a multiwell plate reader.
Compounds are diluted in DMSO prior to addition to assay buffer, the final DMSO concentration in the assay being 1%.
The IC50 is defined as the concentration at which a given compound achieves 50% inhibition of control. Results are shown in Table 1 : Table 1
Figure imgf000060_0001
In Table 1 above, p38α binding potencies (IC50 values) are indicated as follows: <2000-500nM '+'; <500-100nM '++'; 10 -<100nM '+++'; <10nM '++++'. All compounds tested exhibited IC50 values <2000nM; NT not tested. p38 functional assay
Inhibition of cellular p38 depresses the release of TNFα, a functional response which is quantified by measurement of the amount of TNFα in the supernatants of LPS activated THP-1 cells (an immortalised monocytic cell line) or peripheral blood mononuclear cells (PBMCs) isolated from freshly drawn human blood.
Cells seeded in 96 well plates are pre-treated by the addition of p38 inhibitors for 1 h followed by addition of lipopolysaccharide (LPS) to activate cytokine production and release. The amount of TNFα released into the cell supematants is quantified using an R&D Systems enzyme linked immunosorbent assay (ELISA) kit (product DY210) following the manufacturers instructions.
Compounds are diluted in DMSO prior to addition, the final DMSO concentration in the assay being 0.3%. The EC50 is defined as the concentration at which a given compound achieves 50% inhibition of the control. Results are shown in Table 2:
Table 2
Figure imgf000061_0001
In Table 2 above, EC50 values are indicated as follows: <7000-500nM '+'; <500- 10OnM '++'; 10 -<100nM '+++'; <10nM '++++'. All compounds tested exhibited EC50 values <2000nM; NT not tested. Biological assays
Pre-clinical mouse model of COPD inflammation - Tobacco smoke induced pulmonary inflammation.
Previous studies have established that the number of inflammatory cells recovered in the bronchoalveolar lavage (BAL) is significantly elevated 24 h following the final Tobacco Smoke (TS) exposure of 4 or 11 consecutive daily TS exposures, this time point was used in the studies reported here.
Protocols for the exposure of mice to TS, obtaining bronchoalveolar lavage (BAL), preparation of cytospin slides for differential cell counts are as outlined below. Exposure of mice to TS daily for 4 or 11 consecutive days
In this exposure protocol, mice were exposed in groups of 5 in individual clear polycarbonate chambers (27 cm x 16 cm x 12 cm). The TS from the cigarettes was allowed to enter the exposure chambers at a flow rate of 100 ml/min. In order to minimise any potential problems caused by repeated exposure to a high level of TS (6 cigarettes), the exposure of the mice to TS was increased gradually over the exposure period to a maximum of 6 cigarettes. The exposure schedule used for 4 days was as follows:
Day 1 : 4 cigarettes (approximately 32 min exposure)
Day 2: 4 cigarettes (approximately 32 min exposure)
Day 3: 6 cigarettes (approximately 48 min exposure)
Day 4: 6 cigarettes (approximately 48 min exposure)
The exposure schedule used for 11 days exposure was as follows:
Day 1 : 2 cigarettes (approximately 16 min exposure)
Day 2: 3 cigarettes (approximately 24 min exposure)
Day 3: 4 cigarettes (approximately 32 min exposure)
Day 4: 5 cigarettes (approximately 40 min exposure)
Day 5 to 11 : 6 cigarettes (approximately 48 min exposure)
A further group of mice were exposed to air on a daily basis for equivalent lengths of time as controls (no TS exposure). Bronchoalveolar lavage (BAL) analysis
Bronchoalveolar lavage was performed as follows: the trachea was cannulated using a Portex nylon intravenous cannula (pink luer fitting) shortened to approximately 8 mm. Phosphate buffered saline (PBS) was used as the lavage fluid. A volume of 0.4 ml was gently instilled and withdrawn 3 times using a 1ml syringe and then placed in an Eppendorf tube and kept on ice prior to subsequent determinations. Cell counts:
Lavage fluid was separated from cells by centrifugation and the supernatant decanted and frozen for subsequent analysis. The cell pellet was re-suspended in a known volume of PBS and total cell numbers calculated by counting a stained (Turks stain) aliquot under a microscope using a haemocytometer.
Differential cell counts were performed as follows:
The residual cell pellet was diluted to approximately 105 cells per ml. A volume of 500 μl was placed in the funnel of a cytospin slide and centrifuged for 8 min at 800 rpm. The slide was air dried and stained using 'Kwik-Diff solutions (Shandon) as per the proprietary instructions. When dried and cover-slipped, differential cells were counted using light microscopy. Up to 400 cells were counted by unbiased operator using light microscopy. Cells were differentiated using standard morphometric techniques. Drug Treatment
Rodents such as mice and rats are obligate nasal breathers thus oral delivery of test materials (such as therapeutic agents) for inhalation will not produce good lung exposure. As a consequence, delivery of therapeutic agents to the lungs in rodents is generally achieved by intra-nasal, intra-tracheal or inhalation by whole body aerosol exposure in a chamber.
The chamber method utilises large amounts of test material and is generally reserved for inhalation toxicology studies rather than pharmacological efficacy studies. Intra-tracheal administration is a very efficient delivery method as almost all of the test material is delivered to the lungs, but this is quite an invasive technique. For studies in the mouse particularly, it is also quite technically demanding as the diameter of the trachea is quite small. The intranasal route is less invasive than the intra-tracheal route and so is particularly suitable for repeat dosing studies such as the 4-11 day mouse model described below. Following intranasal administration ~50% of the dose administered is delivered to the lungs (Eyles JE, Williamson ED and Alpar HO. 1999, lnt J Pharm, 189(1):75-9). As a surrogate route for oral inhalation, mice were dosed intra-nasally with vehicle (0.2% tween 80 in saline), Example 10 (30 μg/kg), Example 10 (100 μg/kg) or Example 10 (300 μg/kg). The control group of mice received vehicle 1 hr prior to being exposed to air daily for a maximum of 50 minutes per day. TS exposure was conducted for 4 days. BAL was performed 24 h following the final TS exposure. Data management and statistical analysis
All results are presented as individual data points for each animal and the mean value was calculated for each group. Since tests for normality were positive, the data were subjected to a one way analysis of variance test (ANOVA), followed by a Bonferroni correction for multiple comparisons in order to test for significance between treatment groups. A "p" value of < 0.05 was considered to be statistically significant. Percentage inhibitions were automatically calculated within the Excel spreadsheets for the cell data using the formula below:
„. . . „„
% Inhibition = 1 -
Figure imgf000064_0001
x 100
^ 72? vehicle group result — sham group result J
Inhibition data for other parameters were calculated manually using the above formula. Brief description of the figures
Figure 1 is a bar graph that illustrates the effect of intranasal administration to laboratory mice with vehicle (0.2% tween 80 in saline), Example 10 (30 μg/kg), Example 10 (100 μg/kg) or Example 10 (300 μg/kg) on the number of BAL cells induced by tobacco smoke 24 hours post the final exposure.
Figure 2 is a bar graph that illustrates the effect of intranasal administration to laboratory mice with vehicle (0.2% tween 80 in saline), Example 10 (30 μg/kg), Example 10 (100 μg/kg) or Example 10 (300 μg/kg) on the number of BAL neutrophils induced by tobacco smoke 24 hours post the final exposure.
As illustrated in Figure 1 , Example 10 significantly inhibited the BAL cell influx induced by TS at 30, 100 or 300 μg/kg when administered by the intranasal route. Similar findings were observed with BAL neutrophils (Figure 2). The results demonstrate a clear anti-inflammatory effect in the lungs of mice exposed to TS.

Claims

CLAIMS:
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000066_0001
wherein;
R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6-membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II)
Figure imgf000066_0002
wherein n is 1 or 2, and R3 and R4 are independently H or CrC6 alkyl, or R3 and R4 taken together with the nitrogen to which they are attached form a 6- membered heterocyclic ring optionally containing a further heteroatom selected from N and O;
Y is -O- or -S(0)p- wherein p is O, 1 or 2;
A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C3-C6 divalent cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R2NHC(=0)W-;
W is a bond, -NH- or -C(RA)(RB), wherein RA and RB are independently H, methyl, ethyl, amino, hydroxyl or halo; and
R2 is a radical of formula (NIA), (IMB) or (MIC):
Figure imgf000066_0003
(NIA) (NIB) (NIC) wherein m is 0 or 1 ; q is 0, 1 , 2 or 3;
T is -N= or -CH=;
R5 is H or F;
R7 is -CH3; -C2H5; - CH2OH, -CH2SCH3; -SCH3 or -SC2H5;
R8 is -CH3 or -C2H5; and
each occurrence of R6 is independently H, CrC6, hydroxyl or halo; or a single occurrence or R6 is a radical of formula (IVA), (IVB) or (IVC)
* *
Figure imgf000067_0001
(IVA) (IVB) (IVC) while any other occurrence of R6 is independently H, Ci-C6 alkyl, hydroxyl or halo
wherein n and p are as defined above ; and wherein in R6
R61a and R61b are H, alkyl, or R61a and R61b may be joined together with the nitrogen to which they are attached to form a heterocyclic ring optionally containing a further heteroatom selected from N and O.
2. A compound as claimed in claim 1 wherein the divalent radical -W-[A]-Y- has one of the following formulae (B) - (J):
Figure imgf000067_0002
■- Xf • .... Crs - > Hχr° - > HNC^
(B) (C) (D) (E) (H
Figure imgf000067_0003
(G) (H) (I) (J)
3. A compound as claimed in claim 1 having formula (IA):
Figure imgf000068_0001
wherein;
V, V1 X and X' are independently -CH= or -N=; and
R1, R2, Y and W are as defined in claim 1.
4. A compound as claimed in claim 1 having formula (IA1):
Figure imgf000068_0002
wherein Y is O or S and R1 and R2 are as defined in claim 1.
5 A compound as claimed in claim 1 having formula (IB):
Figure imgf000068_0003
wherein;
U is CH or N, and;
R1, R2, Y and W are as defined in claim 1 , with the proviso that when U is
N then W is not NH.
6. A compound as claimed in claim 1 having formula (IB1):
Figure imgf000068_0004
wherein Y is O or S and R1 and R2 are as defined in claim 1
7. A compound as claimed in claim 1 having formula (IC):
Figure imgf000068_0005
(IC) wherein Y is O or S, R2 is as defined in claim 1 , and R1 is phenyl, 5- or 6- membered monocyclic heteroaryl or a radical of formula (II) as defined in claim 1.
8. A compound as claimed in any of the preceding claims wherein R1 is a group of formula (II) as defined in claim 1 wherein the group -NR3R4 is morpholinyl.
9. A compound as claimed in any of claims 1 to 7 wherein R1 is isopropyl or 2,6-dichlorophenyl.
10. A compound as claimed in any of the preceding claims wherein R2 is a radical of formula (INC) as defined in claim 1 , wherein R7 and R8 are each methyl.
1 1. A compound as claimed in any of claims 1 to 9 wherein R2 has formula (MID), (IME), (MIF) or (IUG):
Figure imgf000069_0001
12. A compound as claimed in any of claims 1 to 9 wherein R2 is a radical of formula (MIA) as defined in claim 1 , wherein m is 0.
13. A compound as claimed in any of claims 1 to 9 wherein wherein R2 is a radical of formula (MIB) as defined in claim 1 , wherein (a) T is -CH= and R5 = H; or (b) T is -N= and R5 = H; or (c) T -CH= and R5 = F.
14. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims, together with one or more pharmaceutically acceptable carriers and/or excipients.
15. A composition as claimed in claim 14 which is adapted for inhalation for pulmonary administration.
16. The use of a compound as claimed in any of claims 1 to 13 for the treatment of diseases or conditions which benefit from inhibition of p38 MAP kinase activity.
17. The use as claimed in claim 16 wherein the disease or condition is chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy or airways disease that is associated with pulmonary hypertension.
PCT/GB2010/050257 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors WO2010094956A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU2010215261A AU2010215261A1 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 MAP kinase inhibitors
MA34175A MA33128B1 (en) 2009-02-17 2010-02-16 TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF P38 MAP KINASE
EA201190119A EA201190119A1 (en) 2009-02-17 2010-02-16 DERIVATIVES OF TRIAZOLOPIRIDINE AS MAR-KINASE INHIBITORS p38
US13/201,716 US8557797B2 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives and their therapeutic use
BRPI1005327A BRPI1005327A2 (en) 2009-02-17 2010-02-16 triazolopyridine derivatives as p38 map kinase inhibitors
EP10704973A EP2398798A1 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors
CA2752693A CA2752693A1 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors
CN2010800078222A CN102395586A (en) 2009-02-17 2010-02-16 TRiazolopyridine derivatives as p38 map kinase inhibitors
JP2011549680A JP2012517992A (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as P38 MAP kinase inhibitors
SG2011058823A SG174134A1 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors
MX2011008496A MX2011008496A (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors.
TN2011000380A TN2011000380A1 (en) 2009-02-17 2011-08-03 Triazolopyridine derivatives as p38 map kinase inhibitors
IL214658A IL214658A0 (en) 2009-02-17 2011-08-15 Triazolopyridine derivatives as p38 map kinase inhibitors
ZA2011/05993A ZA201105993B (en) 2009-02-17 2011-08-16 Triazolopyridine derivatives as p38 map kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0902651.9 2009-02-17
GB0902651A GB0902651D0 (en) 2009-02-17 2009-02-17 Pharmaceutical compounds and compositions
GB0908069A GB0908069D0 (en) 2009-05-11 2009-05-11 Pharmaceutical compounds and compositions
GB0908069.8 2009-05-11

Publications (1)

Publication Number Publication Date
WO2010094956A1 true WO2010094956A1 (en) 2010-08-26

Family

ID=42232647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050257 WO2010094956A1 (en) 2009-02-17 2010-02-16 Triazolopyridine derivatives as p38 map kinase inhibitors

Country Status (19)

Country Link
US (1) US8557797B2 (en)
EP (1) EP2398798A1 (en)
JP (1) JP2012517992A (en)
KR (1) KR20110116030A (en)
CN (2) CN102395586A (en)
AU (1) AU2010215261A1 (en)
BR (1) BRPI1005327A2 (en)
CA (1) CA2752693A1 (en)
CL (1) CL2011001977A1 (en)
CO (1) CO6420344A2 (en)
EA (1) EA201190119A1 (en)
IL (1) IL214658A0 (en)
MA (1) MA33128B1 (en)
MX (1) MX2011008496A (en)
PE (1) PE20120655A1 (en)
SG (1) SG174134A1 (en)
TN (1) TN2011000380A1 (en)
WO (1) WO2010094956A1 (en)
ZA (1) ZA201105993B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083206A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
WO2013083604A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
JP2013528205A (en) * 2010-06-10 2013-07-08 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Urea derivatives and their therapeutic use, especially in the treatment of respiratory diseases
WO2014015056A3 (en) * 2012-07-17 2014-04-03 Washington University Anti-mucus drugs and uses therefor
WO2014195400A1 (en) * 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9029378B2 (en) 2011-07-26 2015-05-12 Gruenenthal Gmbh Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands
CN105308044A (en) * 2013-06-06 2016-02-03 奇斯药制品公司 Derivatives of [1, 2, 4]-triazolo-[4, 3-A]-pyridine as p38 MAP kinase inhibitors
US10533014B2 (en) 2014-11-05 2020-01-14 Flexus Biosciences, Inc. Immunoregulatory agents
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637513B2 (en) * 2007-10-24 2014-01-28 Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel antagonists
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN114748622A (en) 2017-10-05 2022-07-15 弗尔康医疗公司 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505321A2 (en) 1991-03-21 1992-09-23 Ciba-Geigy Ag Inhaler
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
WO1997003094A1 (en) 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
EP1052264A2 (en) 1999-05-11 2000-11-15 Pfizer Products Inc. Process for the synthesis of nucleoside analogs
WO2002042298A1 (en) 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2003053930A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2005026124A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
WO2006009741A1 (en) 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
US20060035922A1 (en) 2004-08-12 2006-02-16 Mathias John P Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
WO2006018727A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
WO2006082412A2 (en) 2005-02-03 2006-08-10 Argenta Discovery Limited Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors
WO2007091152A1 (en) 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
WO2008024746A1 (en) 2006-08-21 2008-02-28 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505321A2 (en) 1991-03-21 1992-09-23 Ciba-Geigy Ag Inhaler
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
WO1997003094A1 (en) 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
EP1052264A2 (en) 1999-05-11 2000-11-15 Pfizer Products Inc. Process for the synthesis of nucleoside analogs
WO2002042298A1 (en) 2000-11-21 2002-05-30 Novartis Ag Aminothiazoles and their use as adenosine receptor antagonists
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2003053930A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2005026124A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
WO2006009741A1 (en) 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
US20060035922A1 (en) 2004-08-12 2006-02-16 Mathias John P Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
WO2006018718A2 (en) * 2004-08-12 2006-02-23 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2006018727A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
WO2006082412A2 (en) 2005-02-03 2006-08-10 Argenta Discovery Limited Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors
WO2007091152A1 (en) 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
WO2008024746A1 (en) 2006-08-21 2008-02-28 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Druq Desiqn", 1987, PERGAMON PRESS
"Compounds of general formula (V)", vol. 53, 1980, CHEM. SOC.JPN., pages: 2007 - 11
BADGER ET AL., J. PHARM. EXP. THERA., vol. 279, 1996, pages 1453 - 1461
C. DOMINGUEZ ET AL., EXPERT OPINIONS ON THERAPEUTICS PATENTS, vol. 15, 2005, pages 801 - 816
C.S. LARSEN; J. 0STERGAARD: "Textbook of Drug Design and Discovery", 2002, TAYLOR AND FRANCIS, article "Design and application of prodrugs"
DINARELLO ET AL., REV. INFECT. DISEASE, vol. 6, 1984, pages 51
DUAN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 171, 2005, pages 571 - 578
DUMAS J ET AL: "RECENT DEVELOPMENTS IN THE DISCOVERY OF PROTEIN KINASE INHIBITORS FROM THE UREA CLASS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 7, no. 5, 1 September 2004 (2004-09-01), pages 600 - 616, XP009063727, ISSN: 1367-6733 *
ESCOTT ET AL., BR. J. PHARMACOL., vol. 131, 2000, pages 173 - 176
EYLES JE; WILLIAMSON ED; ALPAR HO, INT J PHARM, vol. 189, no. 1, 1999, pages 75 - 9
G. J. HANSON, EXPERT OPINIONS ON THERAPEUTIC PATENTS, vol. 7, 1997, pages 729 - 733
GRISWOLD ET AL., PHARMACOL. COMM., vol. 7, 1996, pages 323 - 229
HADDAD ET AL., BR. J. PHARMACOL., vol. 132, no. 8, 2001, pages 1715 - 1724
HERLAAR E.; BROWN Z., MOLECULAR MEDICINE TODAY, vol. 5, 1999, pages 439 - 447
J HYNES ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 5, 2005, pages 967 - 985
JEROME K D ET AL: "Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 2, 15 January 2010 (2010-01-15), pages 469 - 473, XP026812512, ISSN: 0960-894X, [retrieved on 20091126] *
KRIEG ET AL., JOURNAL FUER PRAKTISCHE CHEMIE, vol. 329, no. 6, 1987, pages 1123 - 30
L. H. PETTUS; R. P. WURTZ, CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 8, 2008, pages 1452 - 1467
LEE ET AL., IMMUNOPHARMACOLOGY, vol. 47, 2000, pages 185 - 200
MIGLIARA ET AL., FARMACO, vol. 47, no. 1, 1992, pages 111 - 19
P. CHOPRA ET AL., EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 17, no. 10, 2008, pages 1411 - 1425
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties", 2002, WILEY-VCH
STEIN ET AL., ANN. REP. MED CHEM., vol. 31, 1996, pages 289 - 298
T. HIGUCHI; V.J. STELLA: "Pro-druqs as Novel Delivery Systems", vol. 14, ACS SYMPOSIUM SERIES
UNDERWOOD ET AL., AM. J. PHYSIOL. LUNG CELL. MOL., vol. 279, 2000, pages 895 - 902
UNDERWOOD ET AL., J. PHARMACOL. EXP. THER., vol. 293, 2000, pages 281 - 288

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528205A (en) * 2010-06-10 2013-07-08 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Urea derivatives and their therapeutic use, especially in the treatment of respiratory diseases
US9029378B2 (en) 2011-07-26 2015-05-12 Gruenenthal Gmbh Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands
TWI568732B (en) * 2011-12-09 2017-02-01 吉斯藥品公司 Kinase inhibitors
WO2013083206A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
CN105503861A (en) * 2011-12-09 2016-04-20 奇斯药制品公司 Kinase inhibitor
CN103974953A (en) * 2011-12-09 2014-08-06 奇斯药制品公司 Kinase inhibitors
KR20140105516A (en) * 2011-12-09 2014-09-01 키에시 파르마슈티시 엣스. 피. 에이. Kinase inhibitors
CN104039787A (en) * 2011-12-09 2014-09-10 奇斯药制品公司 Kinase inhibitors
KR101994381B1 (en) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. Kinase inhibitors
RU2623734C9 (en) * 2011-12-09 2017-09-18 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Kinase inhibitors
JP2015500260A (en) * 2011-12-09 2015-01-05 チエシ ファルマスーティシ エス．ピー．エー． Kinase inhibitor
JP2015502948A (en) * 2011-12-09 2015-01-29 チエシ ファルマスーティシ エス．ピー．エー． Kinase inhibitor
WO2013083604A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105503861B (en) * 2011-12-09 2017-08-01 奇斯药制品公司 Kinase inhibitor
RU2623734C2 (en) * 2011-12-09 2017-06-29 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Kinase inhibitors
RU2586333C1 (en) * 2011-12-09 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalene-1-yl-urea and their use in treatment, inter alia, diseases of respiratory tract
AU2012347350C1 (en) * 2011-12-09 2017-01-19 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EA025268B1 (en) * 2011-12-09 2016-12-30 Кьези Фармачеутичи С. П. А. Kinase inhibitors
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
AU2012347350B2 (en) * 2011-12-09 2016-09-08 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105968110A (en) * 2011-12-09 2016-09-28 奇斯药制品公司 Kinase inhibitors
WO2014015056A3 (en) * 2012-07-17 2014-04-03 Washington University Anti-mucus drugs and uses therefor
US9187470B2 (en) 2012-07-17 2015-11-17 Washington University Anti-mucus drugs and uses therefor
US9440974B2 (en) 2013-06-06 2016-09-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105308044A (en) * 2013-06-06 2016-02-03 奇斯药制品公司 Derivatives of [1, 2, 4]-triazolo-[4, 3-A]-pyridine as p38 MAP kinase inhibitors
US9181242B2 (en) 2013-06-06 2015-11-10 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
RU2637944C2 (en) * 2013-06-06 2017-12-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Kinase inhibitors
WO2014195400A1 (en) * 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US9359354B2 (en) 2013-06-06 2016-06-07 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US11932601B2 (en) 2014-11-05 2024-03-19 Flexus Biosciences, Inc. Immunoregulatory agents
US10533014B2 (en) 2014-11-05 2020-01-14 Flexus Biosciences, Inc. Immunoregulatory agents
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents

Also Published As

Publication number Publication date
CA2752693A1 (en) 2010-08-26
MA33128B1 (en) 2012-03-01
AU2010215261A1 (en) 2011-09-08
US20120088763A1 (en) 2012-04-12
PE20120655A1 (en) 2012-06-07
MX2011008496A (en) 2011-11-18
ZA201105993B (en) 2012-10-31
CN102395586A (en) 2012-03-28
KR20110116030A (en) 2011-10-24
US8557797B2 (en) 2013-10-15
CO6420344A2 (en) 2012-04-16
CL2011001977A1 (en) 2011-11-18
SG174134A1 (en) 2011-10-28
EP2398798A1 (en) 2011-12-28
CN103483338A (en) 2014-01-01
IL214658A0 (en) 2011-09-27
TN2011000380A1 (en) 2013-03-27
JP2012517992A (en) 2012-08-09
EA201190119A1 (en) 2012-05-30
BRPI1005327A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
US8557797B2 (en) Triazolopyridine derivatives and their therapeutic use
EP2580212B1 (en) Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
RU2623734C9 (en) Kinase inhibitors
EP3004098B1 (en) Kinase inhibitors
EP2788345B1 (en) Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2398777B1 (en) Pyrimidopyridazine derivatives useful as p38 mapk inhibitors
WO2010131030A1 (en) Pyridylurea derivatives and their therapeutic use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080007822.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10704973

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12011501544

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20117018786

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008496

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011001977

Country of ref document: CL

Ref document number: 12337

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 214658

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2752693

Country of ref document: CA

Ref document number: 2010215261

Country of ref document: AU

Ref document number: 594611

Country of ref document: NZ

Ref document number: 2011549680

Country of ref document: JP

Ref document number: 11103685

Country of ref document: CO

Ref document number: 3438/KOLNP/2011

Country of ref document: IN

Ref document number: 001509-2011

Country of ref document: PE

Ref document number: 201190119

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: a201110135

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2010215261

Country of ref document: AU

Date of ref document: 20100216

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010704973

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13201716

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI1005327

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110815